Neurelis, Inc.  
VALTOCO® (diazepam  nasal spray ) 
Protocol DIAZ.001.05 
Confidential/Proprietary Information  STUDY TITLE:  A 12 -Month Open -Label, Repeat -Dose Safety Study of NRL -1 in 
Epilepsy Subjects 
STUDY PHASE:  Phase 3  
PROTOCOL NUMBER:  DIAZ.001.05  
Study ID: [REMOVED] 
Protocol 
Version 4.0 - 28 September 2017   
 
NEURELIS , INC.  
 
INVESTIGATIONAL NEW DRUG PROTOCOL  
 
NRL -1 (INTRANASAL DIAZEPAM ) 
 
PROTOCOL NUMBER DIAZ.001.05 
VERSION 4 
28 SEPTEMBER  2017 
 
 
A 12 -MONTH, OPEN -LAB EL, REPEAT -DOSE SAFETY STUDY OF NRL -1 IN 
EPILEPSY SUBJECTS  
 
SPONSOR:  
 
NEURELIS  INC.  
11682 EL CAMINO REAL , SUITE 255 
SAN DIEGO, CA 92130  
  
CONFIDENTIAL 
 
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 2 CONFIDENTIAL  KEY CONTACTS FOR THE STUDY  
SPONSOR’S  
REPRESENTATIVES:   
Sponsor Contact Richard E. Lowenthal, MSc, MBA  
Program Manager  
Neurelis , Inc.  
Cell: 1 -858-335-1300 
Tel: 1 -858-227-3008  
E-mail: richard@pacificlinkconsulting.com  
 
Study Manager  Robert Hasson  
Project Manager  
Neurelis, Inc.  
Cell:  1 -619-540-6253 
Tel: 1 -858-368-9925  
E-mail: rhasson@pacificlinkconsulting.com  
 
Study Medical Monitor  Sarina Tanimoto, MD, PhD 
Chief Medical  Officer, PLC  
Neurelis , Inc.  
Cell: 1 -858-774-8716  
Tel: 1 -858-227-3008  
E-mail: sarina@pacificlinkconsulting.com  
 
Serious Adverse Event Reporting  Fax: 1 -858-436-1401 
Email: NeurelisSafety@pacificlinkconsulting.com  
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 3 CONFIDENTIAL  TABLE OF CONTENTS  
KEY CONTACTS FOR THE STUDY  .......................................................................................... 2  
LIST OF TABLES  .......................................................................................................................... 6  
LIST OF FIGURES  ........................................................................................................................ 6  
LIST OF APPENDICES  ................................................................................................................. 6  
LIST OF ABBREVIATIONS  ......................................................................................................... 7  
INVESTIGATOR STATEMENT  ................................................................................................ 10  
PROTOCOL SYNOPSIS  ............................................................................................................. 12  
1.0 INTRODUCTION  ............................................................................................................ 16  
1.1 Nonclinical Assessments  ................................................................................................... 17  
1.1.1  Pharmacology  ................................................................................................................... 18  
1.1.2  Toxicology of NRL- 1 and Diazepam  ............................................................................... 18  
1.1.2.1  Single Dose Toxicity Studies  ............................................................................................ 18  
1.1.2.2  Repeated -Dose Toxicology Studies .................................................................................. 19  
1.1.2.3  Genotoxicity and Carcinogenicity Studies........................................................................ 19  
1.1.2.4  Reproductive and Developmental Studies ........................................................................ 20  
1.1.3  Pharmacology and Toxicology of Intravail A3 ................................................................ 20  
1.2 Clinical Experience (Diazepam and NRL -1) ..................................................................... 21  
1.2.1  Clinical Trials with NRL -1 ............................................................................................... 22  
1.2.2  Pharmacokinetics and Product Metabolism in Humans ................................................... 24  
1.3 Study Rationale  .................................................................................................................. 26  
2.0 PURPOSE AND STUDY OBJECTIVES  ........................................................................ 27  
2.1 Purpose .............................................................................................................................. 27  
2.2 Study Objectives  ............................................................................................................... 27  
2.2.1  Primary Objective  ............................................................................................................. 27  
2.2.2  Secondary Objectives ........................................................................................................ 27  
2.3 Description of Study Design ............................................................................................. 27  
2.4 Study Endpoints  ................................................................................................................ 28  
2.4.1  Primary Endpoint .............................................................................................................. 28  
2.4.2  Secondary Endpoints ........................................................................................................ 28  
2.4.3  Randomization/Assignment to Study Drug ...................................................................... 28  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 4 CONFIDENTIAL  2.5 Study Drugs  ...................................................................................................................... 29  
2.5.1  Test Product ...................................................................................................................... 29  
2.5.2  Dose and Dose Justification .............................................................................................. 29  
2.5.3  Bioanalytical Method  ........................................................................................................ 30  
2.6 Concomitant Medications ................................................................................................. 30  
2.6.1  Prior and Concomitant Medications ................................................................................. 30  
2.7 Procedures for Monitoring Subject Compliance............................................................... 30  
3.0 STUDY POPULATION  ................................................................................................... 31  
3.1 Inclusion Criteria  .............................................................................................................. 31  
3.2 Exclusion Criteria  ............................................................................................................. 32  
4.0 SAFETY ASSESSMENTS  ............................................................................................... 32  
4.1 Collection of Adverse Events Data ................................................................................... 32  
4.2 Clinical Laboratory Evaluations ....................................................................................... 33  
4.2.1  Hematology  ....................................................................................................................... 33  
4.2.2  Serum Chemistry  .............................................................................................................. 33  
4.2.3  Urinalysis  .......................................................................................................................... 33  
4.2.4  Urine Drug, Alcohol, and Tobacco Screen ....................................................................... 34  
4.2.5  Other Blood Tests ............................................................................................................. 34  
4.3 Physical Examinations and Medical History  .................................................................... 34  
4.3.1  Physical and Neurological Examination  ........................................................................... 34  
4.3.2  Medical History  ................................................................................................................ 34  
4.4 C-SSRS  ............................................................................................................................. 34  
4.5 ECG ................................................................................................................................... 34  
4.6 Height and Weight ............................................................................................................ 35  
4.7 Vital Signs  ......................................................................................................................... 35  
4.8 Smell Test ......................................................................................................................... 35  
4.9 Nasal Irritation Assessments  ............................................................................................. 35  
4.9.1  Assessment of Nasal Irritation: ......................................................................................... 35  
4.9.2  Assessmen t of Mucosal Erythema:  ................................................................................... 36  
4.9.3  Assessment of Mucosal Edema:  ....................................................................................... 36  
4.9.4  Assessment of Nasal Discharge:  ....................................................................................... 36  
4.9.5  Assessment of Mucosal Crusting:  ..................................................................................... 36  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 5 CONFIDENTIAL  4.9.6  Assessmen t of Mucosal Epistaxis:  .................................................................................... 37  
4.10  Quality of Life questionnaire ............................................................................................ 37  
4.11  Pregnancy Test  .................................................................................................................. 37  
5.0 PHARMACOKINETICS  .................................................................................................. 37  
6.0 PHARMACODYNAMICS ............................................................................................... 37  
7.0 EFFICACY  ....................................................................................................................... 38  
8.0 STUDY VISITS  ................................................................................................................ 38  
8.1 Screening ........................................................................................................................... 38  
8.2 Screening Evaluations (Days -21 to -1) ............................................................................ 38  
8.3 Baseline Evaluations (Day -3 to 0, pre-dose) ................................................................... 39  
8.4 Drug Administration  ......................................................................................................... 40  
8.5 Day 30 to 330 (± 7 days) ................................................................................................... 40  
8.6 Day 365 (± 7 days) ............................................................................................................ 40  
8.7 Treatment beyond Day 365 ............................................................................................... 41  
8.8 Follow Up telephone contact ............................................................................................ 41  
8.9 Termination Procedures .................................................................................................... 41  
9.0 PREMATURE DISCONTINUATION FROM STUDY  .................................................. 41  
10.0  PRODUCT SPECIFICATIONS  ....................................................................................... 42  
10.1  Description  ........................................................................................................................ 42  
10.2  Formulation, Packaging, and Labeling ............................................................................. 43  
10.3  Receipt, Storage and Stability of NRL-1 .......................................................................... 43  
10.4  Preparation of Study Drug ................................................................................................ 43  
10.5  Administration of Study Drug  .......................................................................................... 43  
10.6  Ordering and Distribution of Study Drug ......................................................................... 44  
10.7  Accountability of Study Drugs ......................................................................................... 44  
11.0  SAFETY MONITORING AND ADVERSE EVENTS  ................................................... 45  
11.1  Adverse Events  ................................................................................................................. 45  
11.2  Serious Adverse Events .................................................................................................... 47  
11.2.1  Reporting Requirements for Serious Adverse Events ...................................................... 47  
11.2.2  Recording of Serious Adverse Events .............................................................................. 48  
12.0  STATISTICAL CONSIDERATIONS .............................................................................. 48  
12.1  Sample Size Determination ............................................................................................... 48  
Neurelis, Inc. Protocol DIAZ.001.05 
NRL-1 (Diazepam Intranasal) Version: 4  
 
28 September 2017 6 CONFIDENTIAL  12.2 Safety ................................................................................................................................ 48  
13.0 DATACOLLECTION, STUDY MONITORI NG, AND DATA DISCLOSURE ......... ... 49 
13.1 Data Collection and Reporting ................................. ......................................................... 49  
13.2 Study Monitoring .............................................................................................................. 50  
13.3 Data Disclosure and Sub ject Confiden tiality ................... ................................................. 50  
14.0 PROTECTION OF HUMAN SUBJECTS .................................. ..................................... 51  
14.1 Basic Principles ................................................................................................................. 51  
14.2 Institutional Review Board/Ethics Committee ................... .............................................. 51  
15.0 REFERENCE LIST ................................................ .......................................................... 52  
 
LIST OF TABLES 
Table 1:  Intravail A3 Safety Margins Based on Current NRL-1 Formulation ............................ 21  
Table 2:  Summary of Pharmacoki netic Data from the DIAZ.001.01 Study ............................... 23  
Table 3:  Severity Assessment T erminology for Reporting Adverse  Events (CTCAE v 4.03) .... 46  
Table 4:  Contact Informa tion for SAE Reporting ............... ......................................................... 48  
 
LIST OF FIGURES 
Figure 1:  Diazepam ...................................................................................................................... 16  
 
LIST OF APPENDICES 
APPENDIX A:  SCHEDULE OF STUDY PROCEDURES ..................................................... 54  
APPENDIX B:  COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) ................ 57  
APPENDIX C:  NIH TOOLBOX ODOR IDE NTIFICATION TEST .......................... ............ 77  
APPENDIX D:  QUALITY OF LIFE IN EPILEPSY (QOLIE) ........................... ..................... 78  
APPENDIX E:  DIRECTIONS FOR USE ............................................ .................................... 96  
 
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 7 CONFIDENTIAL  LIST OF ABBREVIATION S 
ABBREVIATION  DEFINITION  
AE adverse event  
AEDs  antiepileptic drugs  
ARS  acute repetitive seizures  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AUC  area under the curve  
AUC 0-t area under the plasma concentration -time curve from 0 to  t hours  
AUC∞  area under the plasma concentration -time curve to infinity  
ß-hCG  serum pregnancy test  
BUN  blood urea nitrogen  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CBC  complete blood count  
CFR  Code of Federal Regulations  
CFSAN  Center for Food Safety and Nutrition  
cGMP  current Good Manufacturing Practices  
Cmax Maximum plasma concentration  
CNS  central nervous system  
CO 2 bicarbonate/carbon dioxide  
CRF  case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
DFU  Directions for Use  
E.coli  Escherichia coli  
ECG  Electrocardiogram  
EPA  Environmental Protection Agency  
FDA  US Food and Drug Administration  
GABA  gamma -aminobutyric acid  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 8 CONFIDENTIAL  ABBREVIATION  DEFINITION  
GRAS  generally recognized as safe  
HbSAg  Hepatitis B surface antigen  
HEENT  head, ears, eyes, nose, and throat  
HIV human immunodeficiency virus  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IM Intramuscular  
IP investigational product  
IRB/EC  Institutional Review Board/Ethics Committee  
IUD intrauterine device  
IV intravenous  
kg kilogram(s)  
LD 50 lethal dose 50% or median lethal dose  
LDH  lactate dehydrogenase  
MRHD  maximum  recommended human dose  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram(s)  
mL milliliter  
NOEL  no observable effect level  
NRL -1.A 100 mg/mL diazepam nasal spray suspension manufactured for Neurelis, Inc.  
NRL -1.B 100 mg/mL diazepam nasal spray solution manufactured for Neurelis, Inc.  
OECD  Organisation for Economic Co -operation and Development  
PBMC  blood peripheral mononuclear cells  
PI principal investigator  
PK pharmacokinetics  
QOLIE  Quality of Life in Epilepsy  
RBC  red blood cell 
SAE  serious adverse event  
SD Standard Deviation  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 9 CONFIDENTIAL  ABBREVIATION  DEFINITION  
SOP standard operating procedure  
TEAE  treatment -emergent adverse event  
t1/2 mean elimination half -life 
tmax time to maximum plasma concentration  
µL microliter  
UDS  unit dose sprayer  
US/USA  United  States of America  
WBC  white blood cell  
WHODD  World Health Organization Drug Dictionary  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 10 CONFIDENTIAL  INVESTIGATOR STATEMENT  
I have read and understand the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in accordance with the Sponsor's guidelines, all applicable government regulations, and the International Conference on Harmonisation Good Clinical Practice Guidelines E6 (ICH -GCP).  
I will maintain accurate source documents from which data are transcribed onto case report forms and accurate drug accountability records that show the receipt and disposition of all study drugs. 
I will provide adequate protocol training to my associates, colleagues, and employees assisting in 
the conduct of the study.  
I will obtain Institutional Review Board/Ethics Committee (IRB/EC) approval of the protocol 
and Informed Consent Form prior to enrollment of subjects in the study. I understand that any modifications to the protocol made during the course of the study must first be approved by the IRB/EC prior to implementation except when such modification is made to remove an immediate hazard to the subject. 
I will ensure that a fully executed IRB -approved Informed Consent Form is obtained from each 
subject prior to initiation of an y study procedures.  
I will report (within 24 hours) any serious adverse event, regardless of relationship to study drug, 
or pregnancy that occurs during the course of the study, in accordance with the procedures described in Section 11.0  of the protocol. I will notify the Sponsor if I become aware that a 
partner of a study subject becomes pregnant while the subject was receiving this study drug. 
I will submit all protocol inclusion/exclusion violations to the Medical Monitor for approval 
prior to enrollment of the subject in the study. I will allow the Sponsor, Neurelis , Inc. (Neurelis) and its agents, as well as the United States 
(U.S.) Food and Drug Administration (FDA) and other regulatory agencies to inspect study 
facilities and pertinent records at reasonable times and in a reasonable manner, ensuring subject confidentiality. If I am notified that this study is to be inspected by a regulator y agency, I will 
notify the Sponsor as soon as possible thereafter (no later than one week).  
This protocol contains information that is proprietary to Neurelis.  The information contained herein is provided for the purpose of conducting a clinical trial for Neurelis.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017 11 CONFIDENTIAL  The contents of this protocol may be disclosed to study personnel under your supervision and to 
your IRB/EC. The contents of this protocol may not be disclosed to any other parties (unless such disclosure is required by government regulations or laws) without the prior written approval of Neurelis.  
 
  __________________________________________ _______________________ Investigator’s Signature  Date  
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 12 CONFIDENTIAL  PROTOCOL SYNOPSIS  
Study Title  A 12 -Month Open- Label, Repeat -Dose Safety Study of NRL -1 in Epilepsy Subjects 
(DIAZ.001.05)  
Phase  Phase 3  
Study Drug  NRL -1 (Intranasal Diazepam)  
Objectives  Primary objective:  
• The primary objective of this study is to assess the safety of diazepam after repeat 
intranasal doses of NRL -1 administered to Epilepsy subjects who experience frequent 
breakthrough seizures or Acute Repetitive Seizures  (ARS) , over a 12 -month period.  
Secondar y objective:  
• To assess the tolerability of diazepam after repeat intranasal administration of NRL -1; 
• To assess the ability of caregivers to administer NRL -1 based on the Directions for Use 
(DFU)  (see APPENDIX E.); 
To assess an improvement in the Quality of Life with NRL -1 use as compared to Diastat.  
Study Design  This is a Phase 3, repeat dose, open -label, safety study in Epilepsy subjects who have freq uent 
breakthrough seizures or ARS.  NRL -1 will be administered as needed to treat bouts of those 
seizures over a 12 -month period of time.  Doses will be defined as 5 milligrams ( mg), 10 mg, 
15 mg, or 20 mg based on the subject’s body weight.  The dosage may be increased or 
decreased for efficacy or safety reasons, if determined by the Principal Investigator that a 
different dose is necessary and there is no safety concern .  A diary will be used to record the 
seizure and NRL -1 administration.  
The study consists of a screening phase, a baseline, a 12 -month treatment period and a follow -
up telephone contact 28 -days after the last dose of NRL -1 or at study termination .  The 
primary purpose of this study is to assess the safety of repeat doses of NRL -1 as intermittent 
chronic therapy to treat frequent break through seizures or  ARS.  Subjects will return to the site 
per the Schedule of Events with all study visits having a ±7 day window around visits.  
Safety assessments include physical and neurological examination including head, ears, eyes, nose, and throat (HEENT), vital signs , laboratories (hematology, serum chemistry, and 
urinalysis), 12 -lead ECGs, and AE assessment.  Concomitant medications will be recorded.  
Columbia -Suicide Severity Rating Scale (C -SSRS for adults or pediatric), Nasal Examination 
and Irritation Assessment (The following will be assessed on separate scales: nasal irritation, 
nasal discharge, mucosal erythema, mucosal edema, mucosal crusting and mucosal epistaxis) , 
Sedation Score Assessment, and Smell Test (NIH Toolbox Odor Identification Test, (1, 2) will 
be conducted at each visit.  A targeted physical examination may be used to evaluate any potentially related side effects.  
Subjects and caregivers will be trained on the proper use of the NRL- 1 nasal sprayer at 
screening period and as needed during treatment period.  The ability of caregivers to administer NRL -1 based on the Directions f or Use (DFU) will be assessed  (see APPENDIX 
E). 
The Quality of Life  in Epilepsy  (QOL IE) questionnaire will be administered to assess the 
quality of life while on NRL -1 compared to basel ine therapy at time of enrollment . 
Naïve subjects may be entered into this study as well as those subjects completing the protocol DIAZ.001.04 are eligible for the long -term safety study (DIAZ.01.05) and may receive 
treatment with NRL -1 under DIAZ.01.05 pr otocol.
 
Sample Size  Up to 100 subjects , at least 30 age 6 to 11 years and up to 70 over 12 years of age, are to be 
enrolled . 
Study 
Population  Subjects with a clinical diagnosis of frequent break through seizures or ARS with bouts of uncontrolled seizures, who, in the opinion of the Investigator, may need a benzodiazepine for 
seizure control.
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 13 CONFIDENTIAL  Main Inclusion 
Criteria  Subjects must meet All of the following inclusion criteria to be enrolled in this study:  
1. Male and female subjects between the ages of  6 and 65 years, inclusive.  
2. Written informed consent to participate in the study.  
3. Subject has a clinical diagnosis of Epilepsy and while on a stable regimen of anti -epileptic 
medication, still experiences bouts of seizures (e.g. frequent break through seiz ures or 
ARS), and who, in the opinion of the Investigator, may need benzodiazepine intervention for seizure control  1 time every other month  on average  (i.e. average 6 times a year). 
4. Subject has a qualified caregiver or medical professional available that can administer study medication in the event of a seizure.  
5. Subjects having either partial or generalized Epilepsy with motor seizures or seizures with clear alteration of awareness.  
6. Female subjects of childbearing potential, defined as havin g a menstrual cycle and who 
are not surgically sterile or less than two (2) years postmenopausal, must complete a 
pregnancy screen and  agree to utilize one of the following forms of contraception during 
the trial and for  21 days after the last dose of stud y drug:  abstinence, hormonal (oral, 
transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), 
intrauterine device (IUD), or vasectomized partner (six months minimum).  Subjects must 
have used the same method for at least one (1) mo nth prior to starting the study . 
7. No clinically significant abnormal findings in the medical history, on the physical examination or electrocardiogram (QTcF<450 msec for males and QTcF<470 msec for 
females).  
Subjects and caregivers must agree to return to the study site for all study visits and must be 
willing to comply with all required study procedures.
 
Main 
Exclusion 
Criteria  Subjects must NOT  meet any of the following Exclusion criteria to be eligible for enrollment:  
1. A history of clinically significant gastrointestinal, renal, hepatic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject. 
2. Subject has had significant traumatic injury, major surgery or open biopsy within 30 days 
prior to study screening.  
3. Subjects with active major depression or a past suicide attempt, or any Suicidal Ideation 
of 3, 4, or 5 or any Suicidal Behavior in Lifetime using Columbia -Suicide Severity Rating 
Scale (C -SSRS).  The pediatric C -SSRS should be used for subjects age 6 to 11.  The adult 
C-SSRS should be used for subjects 12 and greater years of age.  
4. A history of allergic or adverse responses to diazepam or any comparable or similar product.  
5. Participation in a clinical trial other than protocol DIAZ.001.04 within 30 days prior to Day 0 .  Participation in an observational (non -interventional) study is not excluded as 
long as there are no scheduling conflicts with th is study.  
6. Positive serum pregnancy test (ß -hCG) at screening  for subjects age 12 or greater . 
Positive blood screen for Human immunodeficiency virus (HIV), Hepatitis B surface antigen 
(HbSAg), or Hepatitis C, or a positive urine screen for alcohol, or drugs  of abuse , except 
marijuana use for medical reason s.  When marijuana was used for medical reasons  in the 
opinion of the investigator , it is not considered as drug abuse and the patient can be enrolled 
even if the marijuana metabolites in the urine revealed  as positive.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 14 CONFIDENTIAL  Dosage and 
Administration of Study Drug  The initial dose of 5 mg, 10 mg, 15 mg, or 20 mg of NRL -1 will be selected according to the 
subject’s weight (rounded to the nearest kg) based on the following:  
For Children Age 6 -11 Years:  
• 10 kg to 18 kg body weight will receive a 5 mg dose (50 mg/ milliliter [mL], 100 
microliters [µL]) administered as one spray in the left nostril.  
• 19 kg to 37 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 38 kg to 55 kg  will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two 
7.5 mg sprays with one in each nostril (the left nostril will be sprayed first followed 
by the right nostril).  
• 56 kg to 74 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL -1 
administe red as two 10 mg sprays with one in each nostril (the left nostril will be 
sprayed first followed by the right nostril).  
For Age 12 Years or greater:  
• 14 kg to 27 kg body weight will receive a 5 mg dose (50 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 28 kg to 50 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 51 kg to 75 kg will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two 7.5 mg sprays with one in each nostril (the left nostril  will be sprayed first followed 
by the right nostril).  
• Greater than 76 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL -1 
administered as two 10 mg sprays with one in each nostril (the left nostril will be sprayed first followed by the right nostril).  
A second dose may be administered if needed 4 -12 hours after the initial dose of NRL -1.  
Additionally, the dosage may be increased  or decreased  for efficacy or safety reasons, if 
determined by the P rincipal Investigator that a different  dose is necessary and there is no 
safety concern. 
Safety Analysis  AEs will be collected and reviewed to evaluate the safety and tolerability of diazepam nasal 
solution.  Other safety measures will include physical examination,  neurological examination,  
vital sign measurement, and clinical laboratory tests, nasal irritation and examination, and C -
SSRS.  
AE collection will begin on Day 0 after baseline assessments are complete prior to the initial 
treatment with NRL -1 and continue for 28- days after  study termination . AE may be either 
spontaneously reported or elicited during questioning and examination of a subject. AE 
information will be elicited at appropriate intervals by indirect questioning using a non -leading 
question. AEs that occur after dosing in a home setting will be recorded in a diary and reported 
at the next study visit.  Subjects will receive follow -up telephone contact  approximately 28 
days (± 3 days) after  study termination  to determine if any AE has occurred and to follow -up 
on any TEAEs  ongoing since last communication with the subject.  
Nasal irritation will be assessed at baseline and each study visit as well as based on reports of 
any nasal mucosal AEs between visits to the clinical site.  Smell tests will be conducted at 
baseli ne and at each study visit.  The NIH Toolbox Odor Identification Test will be used as 
smell test in this study  (1, 2).  
The C-SSRS  for adults and pediatrics , a measure of suicidal ideation and behavior,  will be 
used to document suicidality in order to classify suicidal events.  Suicidality will be assessed  
at screening for eligibility  (see APPENDIX B). 
The incidence and severity of TEAEs reported during the study and their relationship to study drug will be tabulated.  TEAEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be presented by body system.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 15 CONFIDENTIAL  The World Health Organization Drug Dictionary (WHODD) will be used to classify prior and 
concomitant medications by therapeutic class and preferred term.  Prior and concomitant 
medication usage will be summarized by the number and percentage of subjects receiving each medication within each therapeutic class by dose cohort.  
Study Duration  It is planned that each subject will participate in the primary safety portion of the study for up 
to 414- days, which comprises a 21 -day screening period, baseline, a treatment period of up to 
365-days, and follow -up period up to 28 days.  Subjects may be continued on treatment 
beyond Day 365 at the discretion of the investigator and approval of the sponsor.
 For 
treatment beyond Day 365, it is recommended that subjects are contacted by the Investigator at 
least each 3 months to obtain information on any adverse events.  Study visits after Day 365 
for safety assessment will be recorded in the EDC (CRF) as Unscheduled visits.  
Study Centers  Up to twenty  (20) centers will enroll patients.  
 
   
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 16 CONFIDENTIAL  1.0 INTRODUCTION 
Epilepsy is a significant health problem affecting 50 million people worldwide, including 
2.7 million Americans. Epilepsy negatively impacts quality of life and increases morbidity and mortality. In the US, 25-50,000 deaths each year are attributed to seizures and related causes.  
Seizure emergencies include acute repetitive seizures (ARS), which are defined as intermittent increases of seizure activity while on stable regimens of antiepileptic drugs (AEDs).  The intravenous (IV) formulation of diazepam has been used for over 30 years in the treatment of seizure emergencies, including status epilepticus, but the current standard of care for ARS is a rectal gel formulation of diazepam, Diastat
®(3). 
Diastat rectal gel was approved for marketing by the United States (US) Food and Drug Administration (FDA) in 1997 and is the only diazepam formulation in the US that is approved for ARS.  Although Diastat has an excellent post-approval safety profile and is highly effective in the management of ARS, the product is considered inconvenient and cumbersome, particularly for adult patients, because use of the product requires rectal administration by the caregiver.  Due to this route of administration, the use of Diastat has been limited primarily to the pediatric population, ages 2- 12 years.  
Diazepam, illustrated in  Figure  1 below, is a benzodiazepine anticonvulsant with the chemical 
name; 7 -chloro-1,3-dihydro-1- methyl-5- phenyl -1,4-benzodiazepin-2-one.  It is a colorless to 
light yellow crystalline compound, insoluble in water. The empirical formula is C
16H13ClN 2O 
and the molecular weight is 284.75. 
Figure  1:  Diazepam  
Neurelis is investigating NRL -1 for the treatment of ARS  as an alternative, more convenient to 
use product than the current standard of care, Diastat rectal gel, which is administered rectally at the time of occurrence of an acute seizure.  Two different formulations of NRL- 1 were evaluated 
in an absolute bioavailability study to assess the best absorption profile between a suspension 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 17 CONFIDENTIAL  formulation (NRL-1.A) and a solution formulation (NRL- 1.B).  This initial pharmacokinetics 
(PK) study demonstrated that the solution formulation of NRL- 1 gave the best pharmacokinetic 
characteristics with over 97% absolute bioavailability versus the IV diazepam, and was most 
comparable to the Diastat rectal gel PK profile reported in the label.  As a result of this PK study, 
Neurelis will pursue additional studies with NRL -1 to evaluate the safety and pharmacokinetic 
characteristics of a final commercial product.  
NRL -1 is a novel formulation that includes a proprietary functional excipient called Intravail® 
A3, supplied by Aegis Therapeutics.  Intravail A3 is a GRAS (Generally Recognized As Safe) excipient that is being evaluated in low concentrations (less than 1%) to improve the bioavailability of drugs administered by the intranasal route. The absorption enhancing properties of alkylglycoside surfactants, such as Intravail A3, are believed to occur via loosening of the tight junctions (paracellular) coupled with the fluidization and penetration of cell membranes (transcellular) causing increased drug movement into the cell (4). The NRL-1 
formulation was found to have an optimal bioavailability with the addition of 0.25% 
Intravail  A3. 
A Phase 1 study with NRL-1 was completed in healthy volunteers to evaluate the absorption and PK of two different formulations.  The primary objective of this study was to assess t he 
bioavailability and PK of diazepam after intranasal administration of suspension and solution formulations compared to IV administration to healthy volunteers under fasted conditions. The secondary objective of this study was to assess the safety and to lerability of two formulations of 
diazepam nasal spray after a single intranasal administration of each formulation.  
Based on the pilot PK work completed, it is anticipated that NRL -1 will provide comparable 
exposures of diazepam by the intranasal route o f administration to that observed with Diastat 
rectal gel.  Intranasal delivery is anticipated to be a more convenient and more acceptable route of administration for patients and their caregivers. 
1.1 Nonclinical Assessments  
Given the clinical history of diaz epam, the pharmacology, toxicology, and general safety are well 
understood.  Since it was first approved for marketing more than 40 years ago, a large amount of 
the relevant data on the safety and efficacy of diazepam is derived from clinical use.  The following section provides a brief overview of the literature and public information on the 
nonclinical safety of diazepam for the benefit of the investigator.  
Neurelis has conducted animal PK  studies to assess the bioavailability and tolerability of the 
NRL -1 formulations intended for use in clinical studies.  These studies were conducted in rats, 
rabbits, and dogs.  No unexpected or adverse clinical observations were noted in these studies . 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 18 CONFIDENTIAL  1.1.1 Pharmacology 
Diazepam has anticonvulsant properties unique to some benzodiazepines and is the only product 
that is specifically approved for the treatment of ARS.  Benzodiazepines act via micromolar benzodiazepine binding sites and significantly inhibit de polarization -sensitive calcium uptake in 
rat nerve cell preparations (5).  Diazepam inhibits acetylcholine release in mouse hippocampal 
synaptosomes.  This has been found by measuring sodium- dependent high affinity choline 
uptake in mouse brain cells in vitro , after pretreatment of the mice with diazepam in vivo .  This 
may play a role in explaining diazepam's anticonvulsant properties ( 6).  Diazepam binds with 
high affinity to glial cells in animal cell cultures (7).  Diazepam at high doses has been found to 
decrease histamine turnover in mouse brain via direct action at the benzodiazepine- gamma -
aminobutyric acid ( GABA) receptor complex (8).  Diazepam also decreases prolactin release in 
rats (9).  Diazepam has no effect on GABA levels and no  effect on glutamate decarboxylase 
activity, but has a slight effect on GABA transaminase activity (10). 
Metabolism studies in animals and man have indicated that oral diazepam is rapidly absorbed from the gastrointestinal tract.  Peak blood levels are reached within 1-2 hours afte r 
administration.  The acute half- life is 6 -8 hours with a slower decline thereafter, possibly due to 
tissue storage.  
Limited data are available on nonclinical evaluations of diazepam in safety pharmacology studies for central nervous system (CNS) effects.   However, diazepam has been extensively studied in 
humans and its effects on the CNS are well established clinically.  Diazepam is a benzodiazepine with CNS depressant properties and a somewhat flatter dose-response slope than other sedative-hypnotic drugs.  In laboratory animals, diazepam produces, in varying doses, taming, disinhibitory, sedative, anticonvulsant, muscle relaxant, ataxic, and hypnotic effects. 
Diazepam is relatively devoid of autonomic effects and does not significantly reduce locomotor 
activity at low doses, nor depress amphetamine-induced excitation.  In high doses, it activates the drug metabolizing enzymes in the liver.  Diazepam also possesses dependence liability and may produce withdrawal symptoms, but has a wide margin of safety against poisoning. 
Diazepam has a slight depressive effect on cardiovascular function, but is widely considered to 
have less cardiovascular liability than any other benzodiazepines. 
1.1.2 Toxicology of NRL-1 and Diazepam 
1.1.2.1 Single Dose Toxicity Studies 
The acute toxicity of diazepam is considered to be very low relative to other benzodiazepine 
compounds or other psychotropic drugs.  Generally, after very large acute doses (more than 450 times the typical human dose), respiratory depression and failure ar e the primary causes of 
death in animals.  Acute toxicology studies have been reported in the rat, dog, and mouse ( 11).  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 19 CONFIDENTIAL  Based on these studies a median lethal dose ( LD 50) for diazepam has been established or each 
species.  
LD 50 (oral) rat:  1200 milligrams (mg )/kilogram ( kg) 
 LD 50 (oral) dog:  1000 mg/kg 
 LD 50 (oral) mouse:  700 mg/kg 
1.1.2.2 Repeated -Dose Toxicology Studies 
The toxicology of diazepam is well understood in the literature and based on literature for 
approved marketed products. 
During animal PK studies, a total of 12 formulations of diazepam with Intravail A3 
concentrations up to 0.50% were evaluated in rabbits.  These studies also included evaluation of 
clinical signs and symptoms of toxicology, as well as nasal irritation.  During these studies with intranasal doses up to 10 mg/animal, no unexpected clinical signs of toxicity were observed, with 
the only notable effect of sedation being the expected pharmacological effect of diazepam.  Gross pathology and histopathology evaluations of nasal mucosa from animals after sacrifice did not reveal signs of nasal irritation or other findings that were abnormal as compared to controls.  Thus no significant toxicity or nasal irritation (of selected formulations within the two studies) was observed with any of the NRL-1 formulations tested in the rabbit. 
Intranasal doses of NRL-1 non-aqueous solution we re well tolerated in rats up to 1 mg/day (a 
10 microliters [ µL] dose volume of 100 mg diazepam per milliliter [mL ]) and dogs dosed with 
20 mg/day (a 200 µL dose volume of 100 mg diazepam per mL).  After intranasal administration 
of NRL -1 formulations to rabbits in single dose PK and tolerability studies, and to rats and dogs 
in non- Good Laboratory Practices ( GLP ) intranasal toxicity studies for 28 days, there were no 
significant signs of clinical effects to indicate acute irritation and after sacrifice there were no 
dose- limiting clinical observations or toxicologically important events .  All dose levels were well 
tolerated with only minimal histopathological changes.  A full summary of the repeat-dose toxicology studies is provided in the NRL- 1 Investigator 's Brochure.  
The anticipated safety of the NRL -1 formulations is expected to be similar to diazepam dosed by 
rectal gel administration.  Based on animal studies there does not appear to be any significant acute or chronic irritation of the nasal mucosa. 
1.1.2.3 Genotoxicity and Carcinogenicity Studies 
Diazepam has been reported to have mutagenic activity in the Salmonella typhimurium tester 
strain TA100 in the Ames test (12).  Little or no effect was seen in an assay for chromosomal 
aberrations, performed in Chinese hamster cells in vitro (13). 
Studies by De la Iglesia et al. (14) have demonstrated no increase in tumors frequency after 
feeding diazepam, 75 mg/kg/day, to rats and mice for 104 and 80 weeks, respectively. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 20 CONFIDENTIAL  1.1.2.4 Reproductive and Developmental Studies  
Diazepam has been shown to be teratogenic in mice and hamsters when given orally at single 
doses of 100 mg/kg or greater (approximately eight times the maximum recommended human dose [MRHD=1 mg/kg/day] or greater on a mg/m basis).  Cleft palate and exencephaly are the 
most common and consistently reported malformations produced in these species by administration of high, maternally-toxic doses of diazepam during organogenesis.  Rodent studies have indicated that prenatal exposure to diazepam doses si milar to those used clinically 
can produce long term changes in cellular immune responses, brain neurochemistry, and behavior ( 15). 
1.1.3 Pharmacology and Toxicology of Intravail A3 
The toxicokinetics and metabolism of alkylglycosides, such as Intravail A3 (dodecylmaltoside), have been studied in detail under the Organisation for Economic Co-operation and Development (OECD) Guidelines for Testing of Chemicals.  Orally and nasally administered alkylglycosides 
are hydrolyzed to glucose and the corresponding long chain alcohol.  No toxic metabolites are formed at any stage in the metabolic process.  Dodecyl maltoside is a component (up to approximately 25%) of a mixture of alkylglycosides that are the subject of an application for GRAS status designation by the US FDA Center for Food Safety and Nutrition (CFSAN) and the US Environmental Protection Agency (EPA) based on their use as detergents or surfactants as a component of compounds in food industry and agricultural usages.  With their use in these contexts, there is no established limitation on the oral or topical exposure allowed for humans. 
Twenty (20) GLP nonclinical studies of the pharmacology and toxicology of Intravail A3 have 
been conducted by a number of investigators, as a single agent and in combination with pharmacologically active ingredients in in vitro  studies and in rats, Guinea pigs, rabbits, dogs, 
and monkeys.  Conclusions from the rat and rabbit studies include findings of a regenerative response typically seen following local irritation of nasal mucosa which may be attributed to the use of pipettes for dosing (most likely the result of whole droplet instillation), according to Charles Rivers pathologists.  In contrast, nasal spray actuators were used for dosing in the dog and monkey toxicology studies (for delivery as a mist or fine plume representative of human administration), and these same findings were not observed.  The pathologist concludes the effects were mild and reversible, and should be considered of minimal risk for clinical trial.  
Spack et al. (16)evaluated Intravail A3 for its potential to cause genotoxicity in preclinical studies 
for use as a mucosal surface permeation enhancer of AG284, a protein peptide complex for the treatment of multiple sclerosis.  Intravail A3 was tested in the bacterial reverse mutation assay using S.typhimurium  and Escherichia coli  (E.coli) tester strains.  The maximum dose tested was 
25 mg/plate.  No positive response was observed and hence deemed not mutagenic at 0.5 mg/mL Intravail A3 was also tested in the chromosomal aberration assay using in vitro  mammalian 
cytogenetic tests with human blood peripheral mononuclear cells (PBMCs).  A dose range was established first and then its clastogenic potential was tested.  The maximum concentration tested 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 21 CONFIDENTIAL  was 50 mg/mL.  No statistically significant increases were observed in either the non -activated 
or S9 activated test systems relative to the control group.  Therefore, based on these findings, 
Intravail A3 was not considered a mutagen or genotoxic agent. 
The dosage of NRL-1 that will be used in the current studies is based on patient weight ranges 
from the Diastat label.  The NRL -1 doses administered in these clinical studies will be  5 mg dose 
for patients with a body weight < 20 kg, 10 mg dose for patients with a weight of 20 kg to ≤ 50 kg, a 15 mg dose for patients with a weight of > 50 – 75 kg, and a 20 mg dose for patients with a weight ≥ 75 kg.  The doses used in the clinical studies are supported by clinical 
experi ence and approved dosing given that the bioavailability of NRL-1 is 97%. 
The NRL -1 formulation contains 0.25% Intravail A3 (0.025 mg/100 µL).  Table 1 provides the 
calculated safety margins based on a rat no oberservable effect level ( NOEL ) of 80 µg/day and a 
dog NOEL of 330 µg/day for Intravail A3. 
Table 1:  Intravail A3 Safety Margins Based on Current NRL- 1 Formulation  
Species  NOEL  Human Equivalent 
Dose (HED)  Intravail A3  
Safety Margins  
Rat 0.32 mg/kg (80 µg/day) 0.05 mg/kg 74 - 144 fold 
Dog 0.036 mg/kg (330 µg/day) 0.02 mg/kg 55 - 28 fold 
Human   0.00036 - 0.0007 mg/kg 
(0.025 mg/spray)   
*based on weights for rat, dog, and humans as 0.25 kg, 9.1 kg, and 60 kg, respectively.  
1.2 Clinical Experience (Diazepam and NRL -1) 
Diazepam has been in clinical trials and human use for over 40 years by multiple routes of 
administration including intranasal and IV dosage forms.  In general, the product has a good 
safety profile and has not been associated with any chronic or serious side effects in humans.  Diazepam has been extensively studied and its PK and metabolism in humans is well understood.  
When administered orally, intravenously, or rectally, most of diazepam is extensively and rapidly absorbed, with bioavailability varying from 80 to 100 % and time to maximum plasma 
(t
max) concentration ranging from minutes (IV) to several hours (oral).  
The safety of diaz epam by the intranasal route of administration is also supported by the IV 
formulation as the IV route of administration gave the most rapid t max and highest maximum 
plasma concentration  (C max) of any o ther route of administration.  Doses of diazepam by IV 
administration are safe up to 30 mg administered as  a 20 to 30 minute infusion time in adults, 
according to the FDA product labeling.  Given the bioavailability demonstrated for NRL-1 (97%) in the absolute bioavailability study in comparison to IV diazepam , it is c onsidered that a 
dose of up to 20 mg of diazepam given by intranasal administration would not cause a safety 
concern  even if completely and rapidly absorbed. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 22 CONFIDENTIAL  For IV diazepam, the US product labeling states that the usual recommended dose in older 
children and adults ranges from 2 to 20 mg by IM or IV administration, depending on the indication and its severity.  In some conditions, e.g., tetanus, larger doses may be required.  For seizure emergencies , such as status epilepticus and severe recurren t convulsive seizures, IV 
doses of up to 30 mg diazepam administered  over a 20 to 30 minute time period is approved for 
adults according to US FDA labeling.  Thus, an intranasal dose of 20 mg of diazepam as NRL -1 
should not present  a significant safety risk to subjects. 
1.2.1 Clinical Trials with NRL -1 
An absolute bioavailability study of two formulations of NRL-1 has been completed.  Study DIAZ.001.01 was an open-label, randomized, three- treatment, three -period, six- sequence 
crossover study to evaluate the PK of diazepam after administration of an intranasal suspension (NRL -1.A), 10 mg, or an intranasal solution (NRL-1.B), 10 mg, compared to 5 mg administered 
by IV. Each diazepam dose was separated by a minimum 14 -day washout period.  
Subjects were randomized into 6 sequence groups with 4 subjects per sequence group. The 
sequence of the treatments was randomly assigned, and all subjects received each of the following diazepam treatments:  
• Diazepam nasal spray, suspension (NRL-1.A), single 10- mg intranasal dose  
• Diazepam nasal spray, solution (NRL-1.B), single 10- mg intranasal dose  
• Diazepam IV, 5 mg/mL, administered over 1 minute  
Diazepam was absorbed after intranasal administration of both proprietary formulations to 
humans, with higher exposure after administration as a solution (NRL-1.B) (absolute bioavailability 97%) than as a suspension (NRL-1.A) (absolute bioavailability 67%). With the exception of two  subjects who had longer t
max for the intranasal solution, t max was randomly 
distributed between the two i ntranasal treatments with comparable medians and ranges. The 
difference in exposure between the intranasal solution and intranasal suspension is therefore due to the extent rather than to the rate of absorption. 
The mean elimination half- life (t
1/2) of dia zepam was comparable for the two intranasal 
formulations of diazepam and the IV treatment indicating that there does not appear to be a 
prolonged absorption of diazepam after intranasal administration. 
Differences between the solution and suspension with r espect to the metabolite, 
desmethyldiazepam, were consistent with those for the parent compound. The mean (SD) 
metabolite -to-parent ratios of area under the plasma concentration -time curve to infinity ( AUC ∞), 
uncorrected for molecular weight, were 1.47 (0.28) for the intranasal solution and 1.49 (0.38) for the intranasal suspension, consistent with the ratio of 1.54 (0.43) for the IV. This suggests little or no contribution to the extent of formation of desmethyldiazepam by first-pass metabolism and thus a low likelihood that any of the intranasal- administered diazepam was absorbed from the 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 23 CONFIDENTIAL  gastrointestinal tract afte r swallowing any “run off” from the back of the nose. 
Table 2:  Summary  of P harmacokinetic Data from the DIAZ.001.01 S tudy  
 Diazepam Nasal Spray (10  mg/100μL)  Diazepam Injection  
 NRL -1.A Suspension  NRL -1.B Solution 5 mg/mL IV  
Parameter a  n Mean (SD) b  n Mean (SD) b  n Mean (SD) b 
Cmax (ng/mL)  24 221 (78.6) 24 272 (100) 24 555 (316) 
tmax (h) 24 1.00 (0.6, 2.0)  24 1.50 (0.8, 4.0)  24 0.03 (0.03, 0.50)  
AUC 0-t (h*ng/mL)  24 5229 (1463)  24 7340 (1882)  24 3832 (1150)  
AUC 0-∞ (h*ng/mL)  20 5381 (1409)  20 7338 (2072)  24 4104 (1318)  
λz (h-1) 20 0.0142 (0.0053) 20 0.0155 (0.0046) 24 0.0142 (0.0055) 
t½ (h)  20 56.2 (23.0) 20 49.2 (16.9) 24 56.2 (21.0) 
a: Mean values are presented as arithmetic means.  
b: Median (min, max) reported for t max 
 
The safety results show that administration of intranasal diazepam suspension (NRL-1.A), 
solution (NRL- 1.B), and IV diazepam were well -tolerated. While most (71%) subjects 
experienced at least one treatment -emergent adverse event (TE AE) during the study, the 
frequency of adverse event ( AE) occurrence did not appear to be dependent on diazepam 
formulation, and the AE  profile provided no clear evidence of treatment differences. All TEAEs 
were considered by the Investigator to be of mild or moderate intensity.  
Overall, the most frequently reported TEAEs were epistaxis (7 subjects) and somnolence 
(6 subjects). While AEs of somnolence were more commonly associated with IV diazepam 
(4 subjects) than with either of t he intranasal diazepam formulations (1 subject each), sedation 
scores were similar across treatment groups at most post-dose time points.  
For epistaxis, it is noteworthy that intranasal delivery of diazepam did not appear to be a 
predictor of epistaxis (or nasal irritation). The number of AEs of epistaxis was greater following IV diazepam (5 events) than after administration of NRL-1.A (1 event) or NRL-1.B (3 events). In addition, previous exposure to intranasal diazepam did not appear to influence the ons et of 
nasal bleeding/irritation in the presence of IV diazepam exposure. In this study, nasal bleeding was identified after IV diazepam administration when subjects had no prior exposure to intranasal diazepam and when subjects’ prior exposure to intranasal diazepam did not produce bleeding/irritation.  
In addition to events of epistaxis and somnolence, other AEs reported for more than one subject overall included; headache (5 subjects), nasal discomfort (4 subjects) and nasal inflammation (3 subjects).  No other AE was reported for more than one subject, either within a treatment 
group or overall. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 24 CONFIDENTIAL  There were no AE reports of nasal pain by any subject in any treatment period.  
Of the 24 subjects who received study drug, 13 experienced at least one AE considered by the 
Investigator to be related to treatment. The most commonly experienced treatment- related AEs 
were somnolence (6 events total), nasal discomfort (4 events total), headache (4 events total), and epistaxis (3 events total). 
No subject was withdrawn from the study in response to an adverse event. No serious adverse 
events ( SAEs ) were reported, and no deaths occurred during the study. There were no clinically 
important findings noted in the vital sign data, electrocardiogram ( ECG ) findings, or in the 
individual clinical laboratory data. One subject had a clinically significant finding in the physical 
examination at the end of study assessment; this event, mouth ulceration (an AE), was 
considered by the Investigator to be both mild in severity and unrelated to study drug. 
Conclusion Overall, the results of past clinical studies and the long history of diazepam use in patients, 
support the proposed Phase 3 clinical trial for NRL -1 and the safety of the proposed intranasal 
doses of diazepam intended for this trial.  
1.2.2 Pharmacokinetics and Product Metabolism in Humans  
Oral Administration : 
After oral administration, greater than 90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 –1.5 hours with a range of 0.25 to 2.5 hours. Absorption 
is delayed and decreased when administered with a moderate fat meal. In the presence of food mean lag times are approximately 45 minutes as compared with 15 minutes when fasting. There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting. This results in an average decrease in C
max of 20% in addition to a 27% decrease in area under the curve ( AUC ) (range 15% to 50% ) 
when administered with food. 
In young healthy males, the volume of distribution at steady-state is 0.8 to 1.0 L/kg. The decline 
in the plasma concentration -time profile after oral administration is biphasic. The initial 
distribution phase has a half- life of approximately one hour, although it may range up to 3 
hours ( 3). 
Intravenous Administration: 
IV administration of diazepam results in a tmax at the end of the infusion time and C max dependent 
on the rate of infusion.  Doses of 10 mg given over a 20 to 30 minute infusion time are common in clinical trials and practice.  Doses of up to 30 mg in a 30 mi nute infusion time are allowed in 
the product labeling for IV diazepam.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 25 CONFIDENTIAL  Rectal Administration : 
Diazepam rectal gel is well absorbed following rectal administration, reaching peak plasma 
concentrations in 1.5 hours. The absolute bioavailability of diazepam rectal gel relative to diazepam injectable according to the product labeling of Diastat is 90%. The volume of 
distribution of diazepam rectal gel is calculated to be approximately 1 L/kg. The mean t
1/2 of 
diazepam and desmethyldiazepam following administration of a 15 mg dose of diazepam rectal gel was found to be about 46 hours (CV=43%) and 71 hours (CV=37%), respectively (17). 
Intranasal Administration : 
Several clinical studies with intr anasal formulations of diazepam have been reported in the 
literature.  Generally, absolute bioavailability of these formulations was low (approximately 50%) and have been conducted in both healthy volunteers and patients with similar outcomes.  
Gizurarson et al.  administered a 2 mg  dose of a 20 mg⁄ mL diazepam solution dissolved in 
5%glycofurol in polyethylene glycol 200.  The mean bioavailability was 50.4 ±  23.3% with a 
time to peak concentration of 18 ±  11 minutes (18). 
Lindhardt et al.  evaluated an intranasal formulation of diazepam with doses of 4 and 7 mg in 
polyethylene glycol 300 in seven healthy volunteers as compared to a 5 mg IV dose.  The 
intranasal formulation had a relative bioavailability of 45 % and 42%, a C
max of 99 and 
179 ng⁄m L and a tmax of 18 and 42 minutes  for the 4 and 7 mg doses, respectively ( 19). 
Ivaturi et al.  conducted a study of the bioavailability and tolerability of intranasal diazepam in 
healthy volunteers.  They compared 5 and 10 mg intranasal diazepam doses of their 
investigational formulation with a 5 mg dose of diazepam solution intravenously.  Followi ng the 
5 and 10 mg doses, the median t max were 20 and 30 minutes  respectively and the mean C max were 
134.3 ± 62 and 247.6 ± 61 ng/mL.  Estimated bioavailability was 75% for both doses.  In the same study, a group of subjects was evaluated to compare 5 mg of diazepam and 5 mg of midazolam with intranasal and IV routes of administration.  Intranasal diazepam was rapidly 
absorbed, with a t
max of 28.8 ±  20.96 minutes . Cmax was 179.2 ±  8.85(ng⁄mL ) and half -life was 
22.4 ±  3.45 hours ( 20). 
Results of the DIAZ.001.01 study with NRL-1 are  provided above in Section 1.2.1. 
Intranasal Use of Intravail in Human Subjects: 
Intravail A3 is being evaluated in human clinical trials.  As of September 2014, Intravail A3 has 
been used in: (i) eight intranasal human programs with a total of 13 human studies; and (ii) three human oral programs with a total of five human studies.  These human studies have been conducted in the United States and India and have included more than 280 subjects with over 3,500 aggregate doses.  Each study has been a single dose study with the exception of one 7 day 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 26 CONFIDENTIAL  study with 24 subjects and one six-week study with 75 subjects.  No clinically relevant AEs have 
been observed to date that were attributable to Intravail A3. 
In three (3) completed an d one ongoing clinical studies conducted outside the United S tates with 
an undisclosed active pharmaceutical ingredient, 84 normal subjects have been exposed to 1 to 
3 single 100 µL intranasal doses of Intravail A3 at concentrations of 0.1-0.2%.  Two hundr ed 
thirty -eight (238) AEs have been reported with 237 being mild and of a nature expected with the 
active drug.  One SAE  (pancreatitis) was reported during the study, but the subject had not 
received the reference product containing Intravail A3.  
The current toxicology and clinical studies with Intravail A3 show no evidence of any 
concerning or non-reversible findings at the dose levels anticipated to be used in humans. 
In 2007 alkylpolyglycosides, the class of compounds, which includes Intravail A3, w ere the 
subject of a GRAS Exemption Claim submitted to the FDA (21).  The subject of this claim was 
the use of alkylpolyglycosides as “surfactants for use in the cleaning of foo d products, the 
cleaning of equipment used to process food, the manufacture of products that come in contact 
with food, fruits and vegetables including meat and poultry carcasses, the cleaning of materials that subsequently come in contact with food, paper , cardboard, plastic or stainless steel lines 
and/or production vessels, and the cleaning and sanitizing of surfaces in food preparation areas.” 
In the FDA’s response to the GRAS Exemption Claim (21), the FDA (Office of Food Additive 
Safety, Center for Food Safety and Applied Nutrition) had no questions with respect to the 
conclusion reached by the Applicant, stating that: “Based on the information provided by Cognis, as well as o ther information available to the FDA, the agency has no questions at this 
time regarding Cognis' conclusion that alkylpolyglycosides are GRAS under the intended conditions of use.” The Agency noted that it has not, however, made its own determination regarding the GRAS status of the subject use of alkylpolyglycosides.  Nonetheless, 
alkylpolyglycosides and Intravail A3 are commonly regarded as GRAS (22). 
In September 2005, the US EPA  determined that there is a reasonable certainty of no harm from 
aggregate exposure to residues of C10-C16-alkyl glycosides and that establishing an exemption from the requirement of a tolerance for C10-C16- alkyl glycosides will be safe for the general 
population including infants and children( 23). 
Overall the introduction of Intravail into the NRL-1 formulation is anticipated to provide an absolute bioavailability comparable to Diastat rectal gel with reduced variability and a more convenient, less invasive delivery system.  
1.3 Study Rationale 
Diazepam rectal gel (Diastat) is the only formulation of diazepam indicated for the management of selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity, i.e., ARS . 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 27 CONFIDENTIAL  A diazepam nasal spray is being developed for patients who experience ARS  to provide an 
alternative more convenient and acceptable route of diazepam administration. 
The purpose of this study is to assess the long -term safety of NRL -1. 
2.0 PURPOSE AND STUDY OBJECTIVES  
2.1 Purpose  
The purpose of this study is to assess the safety  of repeat intranasal doses of NRL -1administered 
to Epilepsy subjects. 
2.2 Study Objectives  
2.2.1 Primary Objective  
The primary objective of this study is to assess the safety of diazepam after repeat intranasal 
doses of NRL-1 administered to Epilepsy subjects who experience frequent breakthrough 
seizures or Acute Repetitive Seizures, over a 12 -month period. 
2.2.2 Secondary Objectives  
The secondary objectives of this study include: 
• To assess the tolerability of diazepam after repeat intranasal administration of NRL -1; 
• To assess the ability of caregivers to administer NRL -1 based on the Directions for Use 
(DFU)  (see APPENDIX E); 
• To assess an improvement in the Quality of Life with NRL- 1 use as compared to Diastat.  
2.3 Description of Study Design  
This is a Phase 3, repeat dose, open- label, safety study in Epilepsy subjects who have frequent 
breakthrough seizures or ARS.  NRL -1 will be administered as needed to treat bouts of those 
seizures over a 12 -month period of time.  Doses will be defined as 5  mg, 10 mg, 15 mg, or 20 mg 
based on the subject’s body weight.  The dosage may be increased or decreased for efficacy or safety reasons, if determined by the Principal Investigator that a different dose is necessary and there is no safety concern.  A diary will be used to record the sei zure and NRL- 1 administration.  
The study consists of a screening phase, a baseline, a 12 -month treatment period and a follow-up 
telephone contact 28- days after the last dose of NRL -1 or study termination .  The primary 
purpose of this study is to assess the safety of repeat doses of NRL-1 as intermittent chronic 
therapy to treat frequent break through seizures or ARS.  Subjects will return to the site per the Schedule of Events with all study visits having a ± 7-day window around visits. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 28 CONFIDENTIAL  Safety assessments include physical and neurolog ical examination including head, ears, eyes, 
nose, and throat (HEENT), vital signs, laboratories (hematology, serum chemistry, and 
urinalysis), 12-lead ECGs, and AE  assessment.  Concomitant medications will be recorded.  
Columbia- Suicide Severity Rating Scale (C -SSRS for adults or pediatric), Nasal Examination 
and Irritation Assessment  (The following will be assessed on separate scales:  nasal irritation, 
nasal discharge, mucosal erythema, mucosal edema, mucosal crusting and mucosal epistaxis ),  
Sedation Score Assessment, and Smell Test (NIH Toolbox Odor Identification Test, ( 1, 2) will 
be conducted at each visit.  A targeted physical examination may be used  to evaluate any 
potentially related side effects .   
Subjects and caregivers will be trained on the proper use of the NRL- 1 nasal sprayer at screening 
period and as needed during treatment period.  The ability of caregivers to admini ster NRL -1 
based on the DFU will be assessed  (see APPENDIX E). 
The Quality of Life  in Epilepsy  (QOL IE) questionnaire will be administered to assess th e quality 
of life while on NRL- 1 compared to baseline therapy at time of enrollment .  If under the age of 
11, no Quality of Life questionnaire will be administered. 
Naïve subjects may be entered into this study as well as those subjects completing the protocol 
DIAZ.001.04 are eligible for the long-term safety study (DIAZ.01.05) and may receive treatment 
with NRL -1 under DIAZ.01.05 protocol. 
2.4 Study Endpoints  
2.4.1 Primary Endpoint  
The primary endpoint of this study is safety of NRL -1.  There are no efficacy measures evaluated 
in this study.  
2.4.2 Secondary Endpoints  
The secondary endpoints in this study include: 
• Assessment of the tolerability of diazepam after repeat intranasal administration of NRL -1 
• Assessment of the ability of caregivers to administer NRL -1 based on the DFU 
• Assessment of improvement in the Quality of Life with N RL-1 use as compared to 
Diastat  
2.4.3 Randomization/Assignment to Study Drug  
There are no randomization/assignment s to study drug as this is an open- label study.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
28 September  2017 29 CONFIDENTIAL2.5 Study Drugs  
2.5.1 Test Product  
NRL -1 is a solution formulation of diazepam intended for nasal administration.  NRL- 1 contains 
diazepam, Intravail A3, vitamin E, benzyl alcohol and ethanol.  To provide the range of desired 
doses, NRL-1 will be available with three different concentrations of diaze pam:  
•50 mg/mL
•75 mg/mL
•100 mg/mL
To obtain a 15 mg dose, two sprayers containing the 75 mg/mL formulation will be used with one 100 μL spray in each of nostril. To obtain a 20 mg dose, two sprayers containing the 100 mg/mL formulation will be used with one  100 μL spray in each of nostril. 
NRL -1 is packaged in a disposable molded polymer commercially- available device marketed by 
Aptar Pharma as the UDS (unit dose sprayer).  This single actuation device contains a small glass vial with a rubber stopper.  The Aptar UDS  will deliver an exact dose of 100 µL of NRL -1 
solution.  
2.5.2 Dose and Dose Justification 
An initial dose of 5 mg, 10 mg, 15 mg, or 20 mg of NRL- 1 will be selected according to the 
subject’s weight  (rounded to the nearest kg) based on the following: 
For Children Age 6- 11 Years:  
•10 kg to 18 kg body weight will receive a 5 mg dose (50 mg/mL, 100 µL) administered
as one spray in the left nostril.
•19 kg to 37 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one sprayin the left nostril.
•38 kg to 55 kg will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two7.5 mg sprays with one in each nostril (the left nostril will be sprayed first followed bythe right nostril).
•56 kg to 74 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL- 1 administered as
two 10 mg sprays with one in each nostril (the left nostril will be sprayed first followedby the right nostril).
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 30 CONFIDENTIAL  For Age 12 Years or greater: 
• 14 kg to 27 kg body weight will receive a 5 mg dose (50 mg/mL, 100 µL) administered 
as one sp ray in the left nostril.  
• 28 kg to 50 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 51 kg to 75 kg will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two 7.5 mg sprays with one in each nostril (the left nostril will be sprayed first followed by the right nostril).  
• Greater than 76 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL-1 
administered as two 10 mg sprays with one in each nostril (the left nostril will be sprayed first followed by the right nostril).  
A second dose may be administered if needed 4 -12 hours after the initial dose of NRL-1.  
Additionally, the dosage may be increased or decreased for efficacy or safety reasons, if determined by the Principal Investigator that a different dose is necessary and there is no safety 
concern . 
2.5.3 Bioanalytical Method 
Bioanalytical methods will not be used in this study. 
2.6 Concomitant Medications  
2.6.1 Prior and Concomitant Medications  
Prior medications are defined as medications that were taken within 30 days prior to initial 
dosing with study drug.  
Concomitant medications are defined as medications t aken any time after the start of dosing until 
the final follow-up telephone contact .  
2.7 Procedures for Monitoring Subject Compliance  
NRL -1 will be administered as needed to treat bouts of those seizures over a 12-month period of 
time. A diary will be used to  record the seizure and NRL -1 administration.  At each visit, the 
seizure and dosing information from the diary including the time when the seizure occurs, when 
it ended, the dose, and  date and time of dosing will be recorded to case report form ( CRF ).  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 31 CONFIDENTIAL  3.0 STUDY POPULATION 
The study population will be subjects with a clinical diagnosis of frequent break through seizures 
or ARS with bouts of uncontrolled seizures, who, in the opinion of the Investigator, may need a benzodiazepine for seizure control. 
3.1 Inclusion Criteria  
Subjects must meet All of the following inclusion criteria to be enrolled in this study: 
1. Male and female subjects between the ages of 6 and 65 years, inclusive. 
2. Written informed consent to participate in the study.  
3. Subject has a clinical diagnosis  of Epilepsy and while on a stable regimen of anti- epileptic 
medication, still experiences bouts of seizures (e.g. frequent break through seizures or ARS), 
and who, in the opinion of the Investigator, may need benzodiazepine intervention for seizure control 1 time every other month on average (i.e. average 6 times a year) . 
4. Subject has a qualified caregiver or medical professional available that can administer study medication in the event of a seizure.  
5. Subjects having either partial or generalized Epilepsy with motor seizures or seizures with clear alteration of awareness.  
6. Female subjects of childbearing potential, defined as having a menstrual cycle and who are not surgically sterile or less than two (2) years postmenopausal, must complete a pregnancy screen and agree to utilize one of the following forms of contraception during the study and 
for 21 days after the last dose of study drug:  abstinence, hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (six months minimum).  Subjects must have used the same method for at least one (1) month prior to starting the study. 
7. No clinically significant abnormal findings in the medical history, on  the physical 
examination or electrocardiogram (QTcF  < 450 msec for males and QTcF  < 470 msec for 
females).  
8. Subjects and caregivers must agree to return to the study site for all study visits and must be willing to comply with all required study procedures. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 32 CONFIDENTIAL  3.2 Exclusion Criteria  
Subjects must NOT  meet any of the following Exclusion criteria to be eligible for enrollment:  
1. A history of clinically significant gastrointestinal, renal, hepatic, hematologic, endocrine, 
oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject.  
2. Subject has had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening. 
3. Subjects with active major depression or a past suicide attempt, or any Suicidal Ideation of 3, 
4, or 5 or any Suicidal Behavior in Lifetime using C- SSRS.  The pediatric C -SSRS should be 
used for subjects ages 6 to 11.  The adult C-SSRS should be used for subjects 12 and greater years of age.  
4. A history of allergic or adverse responses to diazepam or any comparable or similar product. 
5. Participation in a clinical trial other than protocol DIAZ.001.04 within 30 days prior to Day  
0.  Participation in an observational (non-interventional) study is not excluded as long as there are no scheduling conflicts with this study. 
6. Positive serum pregnancy test (ß -hCG) at screening  for subjects age 12 years or greater . 
7. Positive blood screen for Human immunodeficiency virus (HI V), Hepatitis B surface antigen 
(HbSAg), or Hepatitis C, or a positive urine screen for alcohol, or drugs of abuse except 
marijuana use for medical reason s.  When marijuana was used for medical reasons in the 
opinion of the investigator, it is not considered as drug abuse and the patient can be enrolled even if the marijuana metabolites in the urine revealed as positive.  
4.0 SAFETY ASSESSMENTS  
4.1 Collection of Adverse Events Data  
Data regarding TEAEs will be collected in this study.  TEAEs are events that are not present at 
baseline, or if present at baseline, have worsened in severity. AEs will be assessed and followed 
up during the treatment period and until follow -up telephone contacts.  
Any AE reported by the subject or noted by the Investigator or his/her designee will be recorded on the CRF regardless of the Investigator opinion of causality.  Events that occur after dosing in a home setting will be recorded in a diary and reported at the next study visit. The following information will be recorded for each AE: description of the event, date and time of onset, date 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 33 CONFIDENTIAL  and time of resolution, severity, causal relationship to study drug, outcome, action taken with the 
study drug and any treatment given. 
All clinically significant abnormal cha nges from baseline in physical examination findings, vital 
signs, and laboratory evaluations will be collected, graded with regards to severity or clinical 
significance, assessed for causal relationship and recorded on the CRF.  
4.2 Clinical Laboratory Evaluations 
Screening blood samples and urine specimens for laboratory evaluation may be collected up to 
21 days prior to initial dose of study drug.  
Subjects with clinically significant abnormal laboratory values during the study will be 
monitored until the value is no longer considered clinically significant or no further change is anticipated.  All abnormal changes from screening  in laboratory values will be collected, graded 
with regards to severity, assessed with regards to causality and recorded in the CRF to be reported as abnormal laboratory findings.  Only clinically significant abnormal laboratory findings associated with clinical sequelae or that require therapeutic intervention are considered 
AEs. All clinical laboratory analyses will be performed at the clinical site and the results will be recorded on the appropriate CRF.  Clinical laboratory reports must be reviewed, signed, and dated by the Investigator.  The Investigator will assess each abnormal test result for clinical significance and the result of the evaluation will be recorded on the CRF. 
4.2.1 Hematology 
Complete blood cell count (CBC) will include red blood cell ( RBC ), RBC morphology, 
reticulocyte count, hemoglobin, hematocrit, white blood cell ( WBC ) with differential, and 
platelet count.  
4.2.2 Serum Chemistry  
Comprehensive metabolic panel will include serum alkaline phosphatase, alanine 
aminotransferase ( ALT ), aspartate aminotransferase ( AST ), glucose, calcium, phosphorus, 
chloride, sodium, potassium, blood urea nitrogen ( BUN ), creatinine, total bilir ubin, albumin, 
total protein, amylase, bicarbonate/carbon dioxide (CO
2), uric acid, and lactate dehydrogenase 
(LDH).  
4.2.3 Urinalysis  
Urinalysis will include appearance, color, pH, specific gravity, glucose, protein, ketones, blood, creatinine clearance, and a detailed microscopic analysis.  Microscopic analysis will be 
performed regardless of macroscopic results and will include the following: WBC, RBC, cast/type, crystal/type, and bacteria.  Standard urinalysis will be conducted on the same day as 
blood chemis try.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 34 CONFIDENTIAL  4.2.4 Urine Drug, Alcohol, and Tobacco Screen  
Urine samples will be collected at screening  for amphetamines, barbitur ates, cocaine metabolites, 
methadone, opiate metabolites, phencyclidine, marijuana metabolites, and alcohol.  When 
marijuana was used  for m edical reason s in the opinion of the investigator, it is not considered as 
drug abuse and the patient can be enrolled even if the marijuana metabolites in the urine revealed as positive. In this case, information about marijuana use for medical reasons  should be entered 
in the CRF page for concomitant medication. 
4.2.5 Other Blood Tests  
The presence of human immunodeficiency virus ( HIV) antibody, Hepatitis B surface antigen 
(HbSAg ), and H epatitis C antibody will be assessed  at screening . 
4.3 Physical Examinations and Medical History  
4.3.1 Physical and Neurological Examination 
The Investigator or designee will perform a physical and neurologic al examination  at screening 
and Day 365. Targeted physical examination may be used during the treatment period to assess 
potentially r elated adverse events . Results will be recorded on t he appropriate page of the CRF.  
4.3.2 Medical History  
A medical history including seizure history will be obtained at screening and baseline. Medical 
history will include demographic data (age, sex, race/ethnicity, etc.).   C- SSRS will be used to 
document suicidality at Screening in order to classify suicidal events . 
4.4 C-SSRS 
The C -SSRS, a measure of sui cidal ideation and behavior, will be used to document suicidality at 
Screening in order to classify suicidal events and on Days 150 and 365 using the C- SSRS.  For 
adults, s creening assessments will use the Baseline/Screening  version of the C- SSRS.  The 
Since Last Visit  version of the C-SSRS will be used for post-dosing assessments.  For children 
age 6 to 11 years old, s creening assessments will use Children’s Baseline/Screening  version and 
Children’s Since Last Visit  version will be used for post- dosing assessments.  
4.5 ECG  
A standard supine (after resting for at least 5 minutes) 12-lead ECG will be performed in 
triplicate by a trained technician  at screening and baseline visits . 
All ECGs are obtained in triplicate . Three consecutive ECGs (each approximately 1 -2 minutes 
apart) are performed . 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 35 CONFIDENTIAL  ECGs will be assessed by the Investigator or a cardiologist, and a comparison to baseline ECGs 
will be performed. The ECG report must be reviewed, signed, and dated by the I nvest igator or 
cardiologist. The original ECG results will be kept on file at the site as sourc e documentation. 
4.6 Height and Weight 
Height will be measured in centimeters.  Body weight will be measured in  kg. Assessments of 
height and weight  will be recorded on the CRF. 
4.7 Vital Signs  
Vital signs (temperature, pulse, respiratory rate, and blood pressure) are to be obtained at 
screening, baseline, and at each visit during the treatment period .  Vital signs will be recorded on 
the CRF.  
4.8 Smell Test  
Smell tests will be conducted at baseline and at each study visit.  The NIH Toolbox for Odor 
Identification Test will be used for smell tests  (1, 2). 
4.9 Nasal Irritation Assessments  
Nasal irritation will be assessed at baseline and each study visit based on the following scales 
outlined in Section 4.9.1 through 4.9.6 below. 
4.9.1 Assessment of Nasal Irritation: 
Objective evaluations of nasal irritation will be assessed at baseline and each study visit based on 
the following assessment scale:  
 Grade 0:  No sign of nasal irritation or mucosal erosion  
 Grade 1A:  Focal nasal mucosal i rritation or Inflammation  
 Grade 1B:  Superficial mucosal erosion 
 Grade 2:  Moderate mucosal erosion  
 Grade 3:  Ulceration  
 Grade 4:  Septal perforation  
The subjects will also be required to report any incident of bleeding or inflammation in- between 
the actual evaluation time points.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 36 CONFIDENTIAL  4.9.2 Assessment of Mucosal Erythema:  
Objective evaluations of mucosal erythema will be assessed at baseline and at each study visit 
using the following scale. 
 Score 0:  No sign of mucosal erythema 
 Score 1:  Mild mucosal erythema (slight redness) 
 Score 2:  Moderate mucosal erythema (redness)  
 Score 3:  Severe mucosal erythema (marked redness)  
4.9.3 Assessment of Mucosal Edema:  
Objective evaluations of mucosal edema will be assessed at baseline and at each study visit  
based on the followin g assessment scale  
 Score 0:  No sign of mucosal edema 
 Score 1:  Mild mucosal edema  
 Score 2:  Moderate mucosal edema  
 Score 3:  Severe mucosal edema  
4.9.4 Assessment of Nasal Discharge:  
Objective evaluations of nasal discharge will be assessed at baseline and at each study visit  based 
on the following assessment scale  Score 0:  No sign of nasal discharge 
 Score 1:  Mild nasal discharge  
 Score 2:  Moderate nasal discharge 
 Score 3:  Severe nasal discharge 
4.9.5 Assessment of Mucosal Crusting:  
Objective evaluations of mucosal crusting will be assessed at baseline and at each study visit  
based on the following assessment scale  
 Score 0:  No sign of mucosal crusting 
 Score 1:  Mild mucosal crusting  
 Score 2:  Moderate mucosal crusting  
 Score 3:  Severe mucosal crusting  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 37 CONFIDENTIAL  4.9.6 Assessment of Mucosal Epistaxis: 
Objective evaluations of mucosal epistaxis  will be assessed at baseline and at each study visit  
based on the following assessment scale  
 Score 0:  No sign of mucosal epistaxis  
 Score 1:  Mild mucosal epistaxis   
 Score 2:  Moderate mucosal epistaxis   
 Score 3:  Severe mucosal epistaxis   
4.10 Quality of Life questionnaire 
The QOLIE  questionnaire will be administered to assess the quality of life while on NRL -1 
compared to baseline therapy at time of enrollment (see APPENDIX D).  QOLIE -AD-48 will be 
used for subjects age 11-18 years of with epilepsy .  Subjects age 18 years or older should 
complete the QOLIE -31-P (APPENDIX D).  If under the age of 11, no Quality of Life 
questionnaire will be administered.  
4.11 Pregnancy Test  
A serum ß-hCG will be administered to females of childbearing potential at screening.  Urine 
pregnancy test is only required for female subjects of child bearing potential. A urine pregnancy 
test will be conducted at baseline and at each visit during the treatment  period. Please note that 
subjects age 6 to 11 are not required to take a pregnancy test.  If a serum pregnancy test is done 
on Day -1, urine pregnancy test does not have to be repeated if done within 72 hours of study initiation (baseline) . 
If a pregnancy occurs in the subject or in the partner of a subject during the course of the study, the Investigator must report it to the Sponsor within 24 hours using the pregnancy notification form provided by the sponsor.  For females who experience pregnancy during the trial, the study medication will be discontinued immediately and the patient will be monitored for any adverse problems with the pregnancy. 
5.0 PHARMACOKINETICS  
No pharmacokinetic measures will be assessed during this trial. 6.0 PHARMACODYNAMICS  
No pharmacody namic measures will be assessed during this trial.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 38 CONFIDENTIAL  7.0 EFFICACY  
No efficacy measures will be assessed during this study.  
8.0 STUDY VISITS  
Refer to APPENDIX A for the Schedule of Study Procedures.   Subjects will return to the site per 
the Schedule of Events with all study visits having a ± 7-day window around visits. 
Within a period of 21 days before dosing, all s creening tests establishing subject eligibility will 
be performed.  
In addition to signing the Informed Consent Form (ICF) and meeting the protocol- specific 
entrance criteria, eligible subjects must agree to return to the study site for all study visits, 
including the confinement period during each treat ment.   The study schedule will be provided in 
writing for the subject’s review and signature acknowledging agreement. 
8.1 Screening  
The Investigator or his/her approved designee must explain the nature of the study protocol and 
associated risks to the potential study participant. The potential participant must be allowed to review the study information and to ask questions before being asked to sign the ICF. Written 
informed consent must be provided by the potential study participant prior to initiation of any screening evaluations or other study-related procedures. The signature date and the name of the individual at the site who obtained the informed consent will be recorded in the subject’s medical record.  
After written informed consent is obtained, the subject will be assigned a screening number and 
will undergo the designated screening procedures listed in APPENDIX A within 21 days prior to 
study drug administration. The Investigator will assess the results of these screening evaluations to determine eligibility for entry into the study according to the inclusion/exclusion criteria listed in Section  3.0. 
8.2 Screening Evaluations (Days -21 to -1) 
After subjects have signed an Institutional Review Board/Ethics Committee  (IRB /EC) approved 
ICF for the purpose of this study, they will begin the screening process.  Screening evaluations may be performed up to 21 days prior to Day 0 . Screening evaluations performed within 24 
hours (Day -1 to Day 0) of dosing do not need to be repeated. 
The following study evaluations and procedures are required to determine eligibility:  
• Medical history  including seizure history, demographics, prior medications, and 
concomitant medications.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 39 CONFIDENTIAL  • The C -SSRS, a measure of suicidal ideation and behavior, will be used to document 
suicidality at screening . The screening assessment will use the Baseline/Screening  
version of the C-SSRS. If the subject reports a history of major depression or a past 
suicide attempt, she/he is not eligible for the study .  The pediatric C -SSRS should be used 
for subjects age 6 to 11.  The adult C-SSRS should be used for subjects 12 and greater years of age.  
• Physical and neurologic al examination, including height and weight measurements. 
• Vital signs consisting of temperature, blood pressure, respiratory rate, and pulse. 
• Blood and serum samples for the following laboratory evaluations : 
o Hematology  
o Serum chemistry  
o Serum ß -hCG (all females)  
o HIV antibody 
o Hepatitis screening  
• Urinalysis  
• Urine drug and alcohol test 
• 12-lead ECG (in triplicate)  
• Subject/caregiver training  
8.3 Baseline E valuations (Day -3 to 0, pre-dose) 
Baseline assessments include the followings:  
• Review of the inclusion/exclusion criteria and medical history  (including seizure history) 
• Any restricted concom itant medications  
• Weight  
• Vital signs  consisting of temperature, respiratory rate, blood pressure, and pulse 
• Urine sample for pregnancy test .  If a serum pregnancy test is done on Day -1, urine 
pregnancy test does not have to be repeated if done within 72 hours of study initiation (baseline)  
• 12-lead ECGs  
• Assessment of t he ability of caregivers to administer NRL -1 
• Quality of Life questionnaire.  If under the age of 11, no Quality of Life questionnaire will be administered.  
• Smell Test (1, 2)  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 40 CONFIDENTIAL  • Nasal examination and  irritation assessments (The following will be assessed on separate 
scales: nasal irritation, nasal discharge, mucosal erythema, mucosal edema, mucosal 
crusting and mucosal epistaxis ) 
• Diary to record seizure and NRL- 1 administration  
• AE assessment  
8.4 Drug Administration 
The calendar date and 24 -hour clock time of all doses will be recorded on the CRF.  A second 
dose may be administered if needed 4-12 hours after the initial dose of NRL-1. 
8.5 Day 30 to 330 (± 7 days) 
Post-dose assessments include the followings (Refer Appendix A1 for the timing  of each 
assessment):  
• Vital signs  consisting of temperature, blood pressure, respiratory rate, and pulse 
• C-SSRS.  The pediatric C -SSRS should be used for subjects age 6 to 11.  The adult C-
SSRS should be used for subjects 12 and greater years of age. 
• Hematology, Serum Chemistry and Urinalysis  
• Urine pregnancy test  
• Smell Test (1, 2) 
• Nasal examination and  irritation assessments (The following will be assessed on separate 
scales: nasal irritation, nasal discharge, mucosal erythema, mucosal edema, mucosal 
crusting and mucosal epistaxis ) 
• Concomitant medications  
• AEs 
• Assessment of the ability of caregivers to administer NRL -1 
• Quality of Life questionnaire.  If under the age of 11, no Quality of Life questionnaire 
will be administered.  
• Diary to record seizure and NRL- 1 administration  
8.6 Day 365 (± 7 days) 
Assessments on Day 365 include the followings: 
• Physical and neurologic al examination including height and weight 
• Vital signs  consisting of temperature, blood pressure, respiratory rate, and pulse 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 41 CONFIDENTIAL  • C-SSRS.  The pediatric C -SSRS should be used for subjects age 6 to 11.  The adult C-
SSRS should be used for subjects 12 and greater years of age. 
• Hematology, Serum Chemistry and Urinalysis  
• Urine pregnancy test  
• Smell Test (1, 2) 
• Nasal ex amination and irritation assessments (The following will be assessed on separate 
scales: nasal irritation, nasal discharge, mucosal erythema, mucosal edema, mucosal 
crusting and epistaxis ) 
• Concomitant medications  
• AEs 
• Assessment of the ability of caregiver s to administer NRL -1 
• Quality of Life questionnaire.  If under the age of 11, no Quality of Life questionnaire 
will be administered.  
• Diary to record seizure and NRL- 1 administration  
8.7 Treatment beyond Day 365 
Subjects may continue treatment on NRL- 1 after th e primary  study period on Day 365 at the 
discretion of the investigator, and until discontinuation of the DIAZ.001.05 study by the Sponsor.  For treatment beyond Day 365, it is recommended that subjects are contacted  by the 
Investigator at least each 3 months to obtain information  on any adverse events.   Study visits 
after Day 365 for safety assessment will be recorded in the EDC (CRF) as Unscheduled visits.  
8.8 Follow Up telephone contact  
Follow-up phone calls 28 days (± 3 days) after the last dose of NRL-1 dosing to determine if any 
AE has occurred and to follow-up on any TEAE(s) ongoing since last communication with the subject  and concomitant medications.   
8.9 Termination Procedures  
At early termination, all subjects will be contacted by phone calls approximately 7 days (± 2 
days) after the subject withdrew the study or after the final dose of NRL-1.  Subject will be 
followed up for AEs  and concomitant medications. 
9.0 PREMATURE DISCONTINUATION FROM STUDY 
A premature discontinuation from study will occur when a subject who signed informed consent ceases participation in this study, regardless of circumstances, prior to completion of the 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 42 CONFIDENTIAL  protocol. Subjects can be prematurely discontinued from the study for one of the following 
reasons:  
• Failure to meet inclusion/exclusion criteria before receiving first dose of study drug has been administered  
• Female subjects who experience pregnancy  
• Potential suicide attempt assessed by C -SSRS and/or Investigator’s assessment  
• Death  
• Significant s afety event that in the opinion of the Investigator warrants discontinuation 
• Lost to follow-up after every attempt has been made to contact the subject, including sending a registered letter  
• Subject withdraws consent 
The principal investigator ( PI) and the IRB/EC reserve the right to prematurely terminate the 
study in the interest of subject safety and welfare. The Sponsor reserves the right to prematurely terminate the study at any time for administrative reasons.  
Subjects will be followed for one- week aft er the administration of the last dose of study drug for 
early termination (Termination Procedures ). 
10.0 PRODUCT SPECIFICATIONS  
10.1 Description  
Diazepam, illustrated in  Figure  1, is a benzodiazepine anticonvulsant with the chemical name; 
7-chloro-1,3- dihydro -1-methyl-5- phenyl -1,4- benzodiazepin -2-one.  I t is a colorless to light 
yellow crystalline compound, insoluble in water. The empirical formula is C
16H13ClN 2O and the 
molecular weight is 284.75. 
NRL -1 is a solution formulation of diazepam intended for nasal administration.  NRL -1 contains 
diazepam, Intr avail A3, vitamin E, benzyl alcohol and ethanol.  To provide the  range of desired 
doses, NRL -1 will be available with four different concentrations of diazepam; 
• 50 mg /mL (5 mg)  
• 100 mg /mL (10 mg) 
• 75 mg/mL (15 mg administered as two 7.5 mg sprays) 
• 100 mg/mL (20 mg administered as two 10 mg sprays with one in each nostril) 
The drug product is manufactured under current Good Manufacturing Practices (cGMP) at a 
contract manufacturing facility.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 43 CONFIDENTIAL  10.2 Formulation, Packaging, and Labeling 
NRL -1 will be supplied for this study as either the 50 mg/mL , 75 mg/mL, or 100 mg/mL 
formulation planned for commercial distribution. 
NRL -1 is packaged in a disposable molded polymer commercially- available device marketed by 
Aptar Pharma as the UDS.  This single actuation device contains a small glass vial with a rubber 
stopper.  The Aptar UDS  will deliver an exact dose of 100 µL of NRL -1 solution.  
Each vial of NRL -1 study drug packaging will be affixed with a single label panel containing the 
following information: 
NRL -1 (Intranasal Diazepam)  
50, 75 or 100 mg/mL (w/v) each vial to deliver 100 µL 
Lot: XXXXX  
10.3 Receipt, Storage and Stability of NRL-1 
NRL -1 will be packaged in a glass vial with the commercially available UDS and placed in 
boxes.  Excursions are permitted to 15- 30 °C (59˚F to 86 ˚F), and after receipt should be stored 
at 15 - 25 °C (59 ˚F-77˚F) [see USP Controlled Room Temperature] until use. 
10.4 Preparation of Study Drug  
NRL -1 is supplied as a solution for intranasal administration.  Dosing is based on the cohort 
assignment.  There is no manipulation or preparation of study drug required.  NRL- 1 will be 
dispensing to study staff responsible for administration to study subjects and reconciliation will occur after dosing. 
10.5 Administration of Study Drug  
Dosing will be according to the follow ing procedure:  
The dose of 5 mg, 10 mg, 15 mg, or 20 mg of NRL- 1 will be selected according to the subject’s 
weight (rounded to the nearest kg) based on the following: 
For Children Age 6- 11 Years:  
• 10 kg to 18 kg body weight will receive a 5 mg dose (50 mg/mL, 100 µL) administered 
as one spray in the left nostril.  
• 19 kg to 37 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 38 kg to 55 kg will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two 7.5 mg  sprays with one in each nostril (the left nostril will be sprayed first followed by 
the right nostril).  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 44 CONFIDENTIAL  • 56 kg to 74 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL- 1 administered as 
two 10 mg sprays with one in each nostril (the left nostril will be sprayed first followed 
by the right nostril).  
For Age 12 Years or greater: 
• 14 kg to 27 kg body weight will receive a 5 mg dose (50 mg/mL, 100 µL) administered 
as one spray in the left nostril.  
• 28 kg to 50 kg will receive a 10 mg dose (100 mg/mL, 100 µL) administered as one spray in the left nostril.  
• 51 kg to 75 kg will receive a 15 mg dose (75 mg/mL, 100 µL) administered as two 7.5 mg sprays with one in each nostril (the left nostril will be sprayed first followed by the right nostril).  
• Greater than 76 kg will receive a 20 mg dose (100 mg/mL, 100 µL) of NRL-1 
administered as two 10 mg sprays with one in each nostril (the left nostril will be sprayed first followed by the right nostril).  
A second dose may be administered if needed 4 -12 hours after the initial dose of NRL -1.  
Additionally, the dosage may be increased or decreased for efficacy or safety reasons, if determined by the Principal Investigator that a different dose is necessary a nd there is no safety 
concern.  
10.6 Ordering and Distribution of Study Drug  
Please contact your Clinical Research Associate or Study Project Manager to order clinical  
supplies. 10.7 Accountability of Study Drugs  
All study drugs received, dispensed, and returned must be accounted for in the study drug 
Dispensing Log, including: 
• Subject number and initials 
• Date study drug was dispensed  
• Quantity of study drug dispensed 
• Quantity of study drug returned  
All study drug received and dispensed by the Investigator will be inventoried and accounted for throughout the study. The study drug must be stored in a restricted area with limited access. Contents of the study drug containers must not be combined. 
The Investigator must maintain an accurate, up to date Dispensing Log for all study drugs 
supplied by the Sponsor. Study drug dispensed for all subjects must be recorded on the Drug 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 45 CONFIDENTIAL  Accountability Form. The study drug Dispensing Log and remaining drug inventory will be 
reviewed at each monitoring visit by the Sponsor- designated clinical monitor . 
The study drug supplied for this study is for use only in subjects properly consented and enrolled into this protocol. Study drugs must be kept in a secure location physically separated from standard clinic or office drug supplies. 
11.0 SAFETY MONITORING AND ADVERSE EVENTS  
11.1 Adverse Events  
Data regarding TEAEs will be collected in this study. TEAEs are events that are not present at 
baseline, or i f present at baseline, have worsened in severity.  
Definition of Adverse Events and Adverse Drug Reactions:  
AEs in the CRF will be classified according to the most recent FDA definitions and in a manner 
consistent with International Conference on Harmonization ( ICH) guidelines.  As such , the 
following definitions will be used: 
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with 
the use of an investigational (medicinal) product (IP) or other protocol-imposed intervention, 
regardless of attribution.  An AE may include intercurrent illnesses or injuries that represent an exacerbation (increase in frequency, severity, or specificity) of pre-existing conditions (e.g., worsening of asthma).  A laboratory abnormalit y will be reported on the “Adverse Event” case 
report form only if it is associated with clinical sequelae or requires therapeutic intervention.  Whenever possible, it is preferable to record a diagnosis as the AE term rather than a series of symptoms rela ting to a diagnosis.  AEs will be coded according to Medical Dictionary for 
Regulatory Activities ( MedDRA ) and graded according to the Common Terminology Criteria for 
Adverse Events ( CTCAE) v 4.03. 
The reporting period for AEs starts on Day 0 after  the baseline assessment is completed  and ends 
28-days (± 3- days)  after study termination  by telephone contact. 
If an AE remains unresolved at final follow-up telephone contact, the subject may  be followed, 
at the Investigator’s discretion, until resolution of the event.  SAEs must be followed until 
resolution by the PI, even if this extends beyond the study-reporting period.  Resolution is defined as the return  to baseline status or stabilization of the condition with the expectation that it 
will remain chronic.  
The Investigator will assess AEs for severity, for relationship to IP, and as to whether the event 
meets one or more of the definitions of an SAE.  The assessments will be recorded on the source documents and AE CRF, using the categories defined below. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 46 CONFIDENTIAL   
Causality 
Category Description  
Unlikely A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which  makes a causal 
relationship improbable, and in which other drugs, chemicals or underlying disease provide plausible explanations. For the purpose of this protocol, the term unlikely will be considered not related to study medication and an “Adverse E vent”.  
Possible A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal maybe lacking or unclear. For the purpose of this protocol, an event that has possible relationship to study medication will be defined as a “Suspected Adverse Drug Reaction”.   
Probable A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable  response on withdrawal
. For the 
purpose of this protocol, an event that has probable relationship to study medication will be defined as an “Adverse Drug Reaction”.  
 
In order to classify adverse events and diseases, preferred terms will be assigned by the sponsor 
or its designee to the original terms entered on the CRF, using MedDRA.  
For those AEs that are not described on the CTCAE v 4.0, such AEs will be graded on a 5-point 
scale (mild, moderate, severe) and reported as indicated on the CRF. Intensity of such an AE is defined as follows: 
Table 3:  Severity Assessment Terminology for Reporting Adverse Events (CTCAE v 4.03) 
CTCAE 
Grade  Common 
Term  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not indicated. 
2 Moderate  Moderate; minimal, local or noninvasive intervention 
indicated; limiting age -appropriate instrumental ADL. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 47 CONFIDENTIAL  CTCAE 
Grade  Common 
Term  Description  
3 Severe  Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self care ADL.  
4 Life-
Threatening  Life-threatening consequences; urgent intervention 
indicated.  
5 Death  Death related to AE  
 
11.2 Serious Adverse Events  
According to the ICH Guidelines for Good Clinical Practice  (GCP) (E6), an SAE is any 
untoward medical occurrence during the course of a clinical investigation that is characterized by 
one or more of the following: 
• Results in death  
• Is life -threatening  
• Requires in -subject hospitalization or prolongation of existing hospi talization  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Important medical events  
Although not an SAE, exposure to study drug during pregnancy, even if no AE is reported in the mother, should be reported within 24 hours. 
11.2.1 Reporting Requirements for Serious Adverse Events  
All SAEs must be reported to the Sponsor by the Investigator, study coordinator, other 
designated study personnel, or clinical research associate within 24 hours of notification of the 
SAE. T o report such events, an SAE form must be completed by the Investigator and sent within 
24 hours by email or fax with relevant information. 
Within the 48 hours following the initial report, the Investigator must provide further information 
on the SAE. This  should include a copy of the completed SAE form, and any other information 
that will assist the understanding of the event. Significant new information on ongoing SAEs should be provided promptly as a follow-up. 
The Investigator also must report all SAEs promptly to the appropriate IRB/EC as required by 
the institution.  
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 48 CONFIDENTIAL  Report SAEs by fax or email to: 
Fax: +1-858-769-0288 Email: NeurelisSafety@pacificlinkconsulting.com  
 
Table 4:  Contact Information for SAE Reporting 
Primary Contact  Sponsor Contact 
Medical Monitor  Clinical Manager:  
Sarina Tanimoto, MD, PhD Robert Hasson 
Mobile: 1-858-774-8716 Mobile: 1-619-540-6253 
Office:  1-858-227-3008  Office:  1-858-368-9925  
Fax: 1-858-436-1401  Fax: 1-858-436-1401  
Email: sarina@pacificlinkconsulting.co
m Email:  rhasson@pacificlinkconsulting.com 
 
11.2.2 Recording of Serious Adverse Events  
All SAE information must be recorded  on the SAE form provided by the Sponsor. Additional 
follow-up information (e.g., test results, autopsy, and discharge summary) must be obtained to 
supplement the SAE report form. A copy of all initial and follow-up reports must be filed with the subject’s CRF . 
12.0 STATISTICAL CONSIDERATIONS  
12.1 Sample Size Determination  
Up to 100 subjects , at least 30 age 6 to 11 years and up to 70 over 12 years of age, are to be 
enrolled . 
12.2 Safety  
Safety data will be summarized by dose group and based on their initial dose level or treatment group (i.e., if a dose reduction occurs they will be considered in their initial group). Descript ive 
statistics will be provided for actual values and change from baseline values for vital signs  and 
change from screening for  clinical laboratory tests (serum chemistry, hematology, and 
urinalysis).  
Nasal examination and  irritation assessments will be conducted to evaluate any effects of the 
NRL -1 formulation on the nasal mucosa.  The following will be assessed on separate scales: 
nasal irritation, nasal discharge, mucosal erythema, mucosal edema, mucosal  crusting and 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 49 CONFIDENTIAL  mucosal epistaxis .  Nasal irritation will be assessed at baseline and each study visit as well as 
based on reports of any nasal mucosal adverse events between visits to the clinical site 
AE collection will begin on Day 0 after baseline assessments are complete prior to the initial 
treatment with NRL -1 and continue for 28-days after Day 365.  AEs may be either spontaneously 
reported or elicited during questioning and examination of a subject.  AE  information will be 
elicited at appropriate intervals by indirect questioning using a non-leading question.  A Es that 
occur after dosing in a home setting will be recorded in a diary and reported at the next study visit.  Subjects will receive follow -up telephone contact approximately 28 days (± 3 days) after 
Day 365 to determine if any AE has occurred and to follow-up on an y TEAEs ongoing since last 
communication with the subject.  
The incidence and severity of TEAEs reported during the study and their relationship to study drug will be tabulated. TEAEs will be coded using the MedDRA and will be presented by body system.  
Smell tests will be conducted at baseline and at each study visit.  The NIH Toolbox for Odor 
Identification Test will be used as smell tests  (1, 2). 
The C -SSRS for adults and pediatrics, a measure of suicidal ideation and behavior, will be used 
to document suicidality in order to classify suicidal events.  Suicidality will be assessed at screening for eligibility.  The pediatric C -SSRS should be used for subjects age 6 to 11.  The 
adult C-SSRS should be used for subjects 12 and greater years of age. 
The World Health Organization Drug Dictionary (WHODD) will be used to classify prior and 
concomitant medications by therapeutic class and preferred term. Prior and concomitant medication usage will be summarized by the number and percentage of subjects receiving each 
medication within each therapeutic class by dose cohort.  
13.0 DATACOLLECTION, STUDY MONITORING, AND DATA DISCLOSURE  
13.1 Data Collection and Reporting 
A CRF will be completed for each subject who receives at least one dose of study drug. All entries on the CRF must be supported by original source documentation (e.g., laboratory reports, medical records) maintained at the investigational site.  
The Investigator will make all safety assessments (AEs, clinical laboratory tests, ECGs, vital 
signs, and results from physical examinations) on an ongoing basis. The Investigator is required to review all entries on the CRF and sign at appropriate time intervals.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 50 CONFIDENTIAL  13.2 Study Monitoring  
All aspects of the study  will be monitored carefully by the Sponsor’s designees with respect to 
cGMP  and standard operating procedure ( SOP) for compliance with applicable government 
regulations. It is the responsibility of the Investigator to provide all study records, including 
CRFs, source documents, etc., for review and inspection by the clinical monitor. 
All CRFs will be 100% source verified against corresponding source documentation (e.g., office 
and clinical laboratory records) for each subject. Clinical monitors will evaluate periodically the progress of the study, including the verification of appropriate consent form procedures, review of drug accountability and preparation procedures, adherence to dosing procedures, and the verification of the accuracy and completeness of  CRFs. Clinical monitors will also ensure that all 
protocol requirements, applicable FDA regulations, other requirements, and Investigator’s obligations are being fulfilled.  
13.3 Data Disclosure and Subject Confidentiality  
Subject medical information obtained as a result of this study is considered confidential. Disclosure to third parties other than those noted below is prohibited. All reports and communications relating to subjects in this study will identify each subject only by their initials and number. Medical information resulting from a subject’s participation in this study may be given to the subject’s personal physician or to the appropriate medical personnel responsible for the subject’s welfare. Data generated as a result of this study are to be avail able for inspection on 
request by FDA or other government regulatory agency auditors, the Sponsor clinical monitor (or designee), and the IRB/EC. 
All laboratory specimens, evaluation forms, reports, and other records that leave the site will be 
identified by a coded number to maintain subject confidentiality. All records will be kept in a 
locked file cabinet. All computer entry and networking programs will be identifiable only by coded numbers. Clinical information will not be released without written permission from the subject, except as necessary for monitoring by the IRB /EC, the FDA, or the study Sponsor.  
Any information, inventions, or discoveries (whether patentable or not), innovations, suggestions, ideas, and reports, made or developed by the Invest igator(s) as a result of 
conducting this study shall be promptly disclosed to the Sponsor and shall be the sole property of the Sponsor. The Investigator agrees, upon the Sponsor’s request and at the Sponsor's expense, to execute such documents and to take such other actions, as the Sponsor deems necessary or appropriate, to obtain patents in the Sponsor’s name covering any of the foregoing. 
The results of this study will be published under the direction of the Sponsor. Results will not be 
published without prior review and approval by the Sponsor. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 51 CONFIDENTIAL  14.0 PROTECTION OF HUMAN SUBJECTS  
14.1 Basic Principles  
This research will be carried out in accordance with the clinical research guidelines established 
by the Basic Principles defined in the U.S. 21 Code of Federal Regulations (CFR) Parts 11, 50, 56, and 312, the principles enunciated in the Declaration of Helsinki concerning medical research in humans (“Ethical Principles for Medical Research Involving Human Subjects,” Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996), and the GCP guidelines of the ICH of the Technical Requirements for Registration of Pharmaceuticals for  Human Use, ICH E6 (May 1996). 
14.2 Institutional Review Board/Ethics Committee  
The Investigator agrees to provide the IRB/EC with all appropriate material, including a copy of the ICF. The study will not be initiated until the Investigator obtains written approval of the 
research plan and the ICF from the appropriate IRB/EC and copies of these documents are 
received by the Spons or. Appropriate reports on the progress of this study will be made by the 
Investigator to the IRB/EC and Sponsor in accordance with applicable government regulations and in agreement with the policies established by the Sponsor. The Sponsor ensures that the IRB/EC complies with the requirements set forth in 21 CFR Part 56. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 52 CONFIDENTIAL  15.0 REFERENCE LIST 
1. NIH. NIH Toolbox Odor Identification Test NIH [Available from: 
http://www.nihtoolbox.org/WhatAndWhy/Sensation/Olfaction/Pages/NIH-Toolbox-Odor-Identification -Test.aspx . 
2. Dalton P, Doty RL, Murphy C, Frank R, Hoffman HJ, Maute C, et al. Olfactory assessment using the NIH Toolbox. Neurology. 2013;80(11 Suppl 3):S32-6. 
3. Valium. Prescribing Information. Valeant Pharmaceuticals. 2007. 4. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced 
increases in nasal peptide drug delivery with morphological changes in nasal epithelia l cells. 
Journal of pharmaceutical sciences. 2004;93(9):2205-13. 
5. Taft WC, DeLorenzo RJ. Micromolar-affinity benzodiazepine receptors regulate voltage-
sensitive calcium channels in nerve terminal preparations. Proceedings of the National Academy of Scien ces of the United States of America. 1984;81(10):3118-22. 
6. Miller JA, Richter JA. Effects of anticonvulsants in vivo on high affinity choline uptake in vitro in mouse hippocampal synaptosomes. British journal of pharmacology. 1985;84(1):19-25. 
7. Gallage r DW, Mallorga P, Oertel W, Henneberry R, Tallman J. [3H]Diazepam binding in 
mammalian central nervous system: a pharmacological characterization. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 1981;1(2):218-25. 
8. Oish i R, Nishibori M, Itoh Y, Saeki K. Diazepam-induced decrease in histamine turnover 
in mouse brain. European journal of pharmacology. 1986;124(3):337-42. 9. Grandison L. Suppression of prolactin secretion by benzodiazepines in vivo. 
Neuroendocrinology. 1982;34(5):369-73. 
10. Battistin L, Varotto M, Berlese G, Roman G. Effects of some anticonvulsant drugs on 
brain GABA level and GAD and GABA-T activities. Neurochemical research. 1984;9(2):225-31. 
11. Clark G. Clarke's Isolation and Identification of Drugs. 1st ed: Pharmaceutical Press; 
1978. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version: 4 
 
28 September  2017 53 CONFIDENTIAL  12. Batzinger RP, Ou SY, Bueding E. Antimutagenic effects of 2(3)- tert-butyl-4-
hydroxyanisole and of antimicrobial agents. Cancer research. 1978;38(12):4478-85. 
13. Matsuoka A, Hayashi M, Ishidate M, Jr. Chromosomal aberration tests on 29 chemicals 
combined with S9 mix in vitro. Mutation research. 1979;66(3):277-90. 
14. de la Iglesia FA, Barsoum N, Gough A, Mitchell L, Martin RA, Di Fonzo C, et al. 
Carcinogenesis bio assay of prazepam (Verstran) in rats and mice. Toxicology and applied 
pharmacology. 1981;57(1):39-54. 
15. Diastat Prescribing Information. FDA: Valeant Pharmaceuticals Int'l.; 2014.  
16. Spack EG, Wehner NG, Winkelhake JL. Preclinical and Pharmacological Studies of 
AG284, a Soluble HLA- DR2:Myelin Basic Protein Peptide Complex for the Treatment of 
Multiple Sclerosis. CNS Drug Reviews. 1998;4(3):225.46. 
17. Diastat. Valium Prescribing Information. 2010. 18. Gizurarson S, Bechgaard E. Intranasal administration of insulin to humans. Diabetes 
research and clinical practice. 1991;12(2):71-84. 
19. Lindhardt K, Gizurarson S, Stefansson SB, Olafsson DR, Bechgaard E. 
Electroencephalographic effects and serum concentrations after intranasal and intravenous administratio n of diazepam to healthy volunteers. British journal of clinical pharmacology. 
2001;52(5):521-7. 
20. Ivaturi VD, Riss JR, Kriel RL, Cloyd JC. Pharmacokinetics and tolerability of intranasal 
diazepam and midazolam in healthy adult volunteers. Acta neurologi ca Scandinavica. 
2009;120(5):353-7. 21. Center for Food Safety and Nutrition/Office of Food Additive Safety FaDA. Agency 
Response Letter GRAS Notice No. GRN 000237. 14 October 2008. 
22. Dandiker Y. Handbook of Pharmaceutical Excipients2000. 23. Environmental. 40 CFR Part 180. 
 
 
 APPENDIX A: SCHEDULE OF STUDY PROCEDURES  
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  3 
 
28 September 2017  55 CONFIDENTIAL  Appendix A1:  Schedule of Study Procedure  
a. Screening evaluations must be performed within 21 days prior to dosing on Day 0.  Screening evaluations performed within 24 h ours (Day -1 to Day 0) of dosing do not need to be repeated.  
b. Baseline evaluations will be performed within 72 hours prior to study initiation on Day 0.  Baseline assessment may be conducted at clinic.  
c. Subjects will receive follow -up telephone contact approximately 28 days (± 3 days) after study termination.  
d. Study window at visits from Days 30 to 365 is ± 7 days.  
e. Subjects that continue on therapy after Day 365 should be contacted to solicit information on potential adverse events at lea st each 3 months.  Any site visits for standard  of care evaluations should 
be recorded in the EDC (CRF) as Unscheduled vis its. 
f. C-SSRS, a measure of suicidal ideation and behavior, will be used to document suicidality in order to classify suicidal events.  The pediatric C -SSRS should be used for subjects age 6 to 11.  The 
adult C -SSRS should be used for subjects 12 and greater years of age (see APPENDIX B ). 
g. Targeted physical examinations may be used during the treatment period to evaluate potentially related adverse events. 
h. Vital signs (temperature, pulse , respiratory rate , and blood pressure) are to be obtained.  
i. Weight only.  Study Procedure  Screeninga Baselineb Treatment period and Visit Days  Follow Up 
telephone 
contactc 
Study Day  Day -21 to  
Day -1 Day -3 to Day 
0 Day 
30d Day 
90d Day 
150d Day 
210d Day 
270d Day 
330d Day 
365d Day 
>365e 28 Days after 
Termination 
Signed informed consent  X           
Inclusion/Exclusion Criteria  X X          
Medical history including seizure history  X X          
Columbia -Suicide Severity Rating Scale  (C-
SSRS)f X    X    X   
Physical and Neurologicalexam (including 
HEENT)g X        X   
Vital signsh X X X X X X X X X   
Height and Weight  X Xi       X   
Hematology, Serum Chemistry and Urinalysis  X    X  X  X   
Serum or urine ß -hCG (Pregnancy)j X X X X X X X X X   
HIV Antibody and Hepatitis Testk X           
Urine Drug  and Alcohol Screenl X           
Prior and Concomitant medication assessment  X X X------------------------- ------------------------------- ------ ------------   X 
Adverse event assessmentm  X X---------------------------- --------- ------------------------ ------------------ ------- X 
ECG (12 -Lead in triplicate)n X X          
Smell Testo  X X X X X X X X   
Assessment of the ability of caregivers to 
administer NRL -1p  X X  X  X  X   
Nasal Examination and Irritation Assessmentq  X X X X X X X X   
Quality of Life in Epilepsy questionnaire  
(QOLIE)r  X X  X  X  X   
NRL -1 Dispenseds  X X------ ------------ -------------- ----------------------------------- --------------------   
Diary to record seizure and NRL -1 administration   X X------------------------------------------------------ ------- ------------------- ------ -  
Subject/caregiver trainingt X  X---------------------------- ------------------------------------ ----------------- ------  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  3 
 
28 September 2107  56 CONFIDENTIAL  j. A serum (ß -hCG) pregnancy test will be administered to females of childbearing potential at screening. Pregnancy test will be done with urine at baselin e and at the visits during the treatment 
period. If a serum pregnancy test is done on Day -1, urine pregnancy test does not have to be repeated if done within 72 hours of study initiation (baseline).   
k. Hepatitis B surface antigen (HbSAg), or Hepatitis C  
l. When marijuana is used for medical reasons in the opinion of the investigator, it is not considered as drug abuse and the patient can be enrolled even if the marijuana metabolites in the urine 
revealed as positive. In this case, information about marijuana use should be entered in the CRF page for concomitant medication.  
m. Adverse event assessment is continuous from Day 0 after baseline assessments are complete.  Events that occur after dosing in  a home setting will be recorded in a diary and reported at the ne xt 
study visit.  
n. ECG is to be performed in triplicate. Three consecutive ECGs (each approximately 1 -2 minutes apart) are performed. 
o. Smell tests will be conducted at baseline and at each visit. The NIH Toolbox Odor Identification Test will be used as smell t ests. 
p. Ability of caregivers to administer NRL -1 will be assessed.  
q. Nasal examination and scoring for nasal irritation, mucosal erythema, mucosal edema, nasal discharge, mucosal crusting and mucosal epistaxis  will be performed at baseline and at each site visit . 
r. QOLIE questionnaire will be administered to assess the quality of life while on NRL -1 compared to baseline therapy at time of enrollment  (see APPENDIX D ).  If under the age of 11, no Quality 
of Life q uestionnaire will be administered.  
s. NRL -1 may be dispensed  to treat bouts of uncontrolled seizures (frequent break through seizures or ARS) after baseline procedures completed.   The amount of drug dispense d is dependent on the 
investigators judgment and anticipated need of the subjects to cover the period between study visits, but should not exceed the amount needed to treat 5 s eizure episodes a month. 
t. Subjects and caregivers will be trained based on the Direction for Use (DFU) for the proper use of the NRL -1 nasal sprayer.  Training may be given as needed during the treatment period.   Primary 
caregivers who are trained may train other secondary caregivers. 
 
 APPENDIX B: COLUMBIA SUICIDE SEVERITY 
RATING SCALE (C -SSRS)  
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  3 
 
28 September 2017  58 CONFIDENTIAL  APPENDIX B:  Columbia Suicide Severity Rating Scale (C -SSRS)  
The Columbia  Suicide Severity Rating Scale (C -SSRS),  a measure of suicidal ideation and behavior, 
will be used to document. For adults, s creening assessments will use the Baseline/Screening  version 
of the C-SSRS.  The Since Last Visit  version of the C-SSRS will be used for post-dosing 
assessments.  For children age 6 to 11, s creening  assessments will use Children’s 
Baseline/Screening  version and Children’s Since Last Visit  will be used for post-dosing 
assessments.   
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  59 CONFIDENTIAL   
COLUMBIA- SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS)  
Baseline/Screening Version  
Version 1/14/09 
 
  
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; 
Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J.   
 
Disclaimer:  
This scale is intended to be used by individuals who have received training in its administration. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale. 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia 
Suicide History Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center 
for the Neuroscience of Mental Disorders (CCNMD), New York State Psychiatric Institute, 1051 
Riverside Drive, New York, NY, 10032. (Oquendo M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First [Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 
1051 Riverside Drive, New York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu  
© 2008 The Research Foundation for Mental Hygiene, Inc. 
 
 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  60 CONFIDENTIAL  SUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section. If the 
answer to question 2 is “yes”, ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete “Intensity of Ideation” section below.  Lifetime: 
Time 
He/She 
Felt Most 
Suicidal  Past 6 
Months  
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
If yes, describe:   
Yes      No  
□    □   
Yes    No 
□   □  
2.  Non -Specific Active Suicidal Thoughts  
General non -specific thoughts of wanting to end one’s life/commit suicide (e.g., “I’ve thought about killing myself” ) 
without thoughts of ways to kill oneself/associated methods, intent, or plan during the assessment period.  
Have you actually had any thoughts of killing yourself?  
 
If yes, describe:  
    Yes   No  
    □   □   
Yes    No 
□   □  
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act  
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is 
different than a specific plan with time, place or method details worked out (e.g., thought of method to kill self but not a 
specific plan).  Includes person who would say, “I thought about taking an overdose but I never made a specific plan as 
to when, where or how I would actually do it…and I would never go through with it.”  
Have you been thinking about how you might do this?  
 
If yes, describe:   
Yes     No 
 □    □   
Yes    No 
□   □  
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan  
Active suicidal thoughts of killing oneself and subject reports having some intent to  act on such thoughts , as opposed to 
“I have the thoughts but I definitely will not do anything about them.”  
Have you had these thoughts and had some intention of acting on them?  
 
If yes, describe:   
   Yes      
No 
□    □   
Yes    No 
□   □  
5.  Active Suicidal Ideation with Specific Plan and Intent  
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.  
Have you started to work out or worked out the details of how to kill yourself? Do y ou intend to carry out this plan?  
 
If yes, describe:   
Yes      No 
 □    □   
Yes    No 
□   □  
INTENSITY OF IDEATION  
The following features should be rated with respect to the most severe type of ideation (i.e., 1 -5 from above, 
with 1 being the least severe and 5 being the most severe).  Ask about time he/she was feeling the most 
suicidal.  
 
Lifetime  -           Most Severe Ideation:  _______                  
________________________________________  
                         Type # (1- 5)                                                 Description of  Ideation 
 
Past 6 Months  - Most Severe Ideation:  _______                   
________________________________________  
                        Type # (1 -5)                                                 Description of  Ideation  Most  
Severe  Most 
Severe  
Frequency  
How many times have you had these thoughts?  
(1) Less than once a  week    (2) Once a week   (3)  2 -5 times in week    (4) Daily or almost daily    (5) Many times 
each day   
 
____  
____ 
Duration  
When you have the thoughts how long do they last?  
(1) Fleeting - few seconds or minutes                                                 (4) 4 -8 hours/most of day  
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or con tinuous  
(3) 1 -4 hours/a lot of time  ____  ____  
Controllability  
Could/can you stop thinking about killing yourself or wanting to die if you want to?  
(1) Easily able to control thoughts                                                      (4) Can control thoughts  with a lot  of difficulty  
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts  
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts  ____  ____  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  61 CONFIDENTIAL   
  Deterrents  
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from 
wanting to die or acting on thoughts of committing suicide?  
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop  you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply  
 ____  ____  
INTENSITY OF IDEATION  
Reasons for Ideation  
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to 
end the pain or stop the way you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?  
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you 
couldn’t go on  
(2) Mostly to get attention, revenge o r a reaction from others                     living with the pain or how you were 
feeling)  
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you 
couldn’t go on  
       and to end/stop the pain                                                                         living with the pain or  how you were 
feeling)  
                                                                                                                 (0)  Does not apply  ____  
 ____  
 
Version 1/14/09 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  62 CONFIDENTIAL  SUICIDAL BEHAVIOR  
(Check all that apply, so long as these are separate events; must ask about all types)  Lifetime  
Actual Attempt:  
A potentially self -injurious act committed with at least some wish to die, as a result of  act. Behavior was in part thought of as 
method to kill oneself. Intent does not have to be 100%.  If there is  any intent/desire to die associated with the act, then it can 
be considered an actual suicide attempt. There does not have to be any injury or harm , just the potential for injury or 
harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results, this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinic ally from the behavior or 
circumstances. For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be inferred 
(e.g., gunshot to head, jumping from window of a high floor/story). Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt?  
Have you done anything to harm yourself?  
Have you done anything dangerous where you could have died?  
What did you do?  
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you _____?  
Or Did you think it was possible you could have died from_____?  
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, 
feel better,  
get sympathy, or get something else to happen )?  (Self-Injurious Behavior without suicidal intent)  
If yes, describe:  
 
Has subject e ngaged in Non -Suicidal Self -Injurious Behavior?  Yes     No  
□   □  
 
 
  
 
  
Total # of 
Attempts  
 
______ 
  
 
  
 
 Yes    No 
□   □  
Interrupted Attempt:  
When the person is interrupted (by an outside circumstance) from starting the potentially self -injurious act(if  not for that, 
actual attempt would have occurred).  
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather  
than an interrupted attempt. Shooting: Person has gun pointed toward self, gun  is taken away by someone else, or is somehow 
prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is 
poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck but has not yet started to hang 
- is stopped from doing so.  
Has there been a time when you started to do something to end your life but someone or something 
stopped you before you actually did anything?  
If yes, describe: 
 Yes      No  
□   □  
 
 
 
Total # of 
interrupted  
 
______ 
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in 
any self -destructive behavior. Examples are similar to interrupted attempts, except that the individual stops him/herself, 
instead of being stopped by something else.  
Has there been a time when you started to do something to try to end your life but you stopped yourself 
before you actually did anything?  
If yes, describe: 
 Yes      No 
□   □  
 
 
Total # of 
aborted  
 
______ 
Preparatory Acts or Behavior:  
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or 
thought, such as assembling a specific method (e.g., buying pills, purchasing a gun) or preparing for one’s death by suicide 
(e.g., giving things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as 
collecting pills, getting a gun, giving valuables away or writing a suicide note )? 
If yes, describe: 
  
 
Yes      No  
□   □  
Suicidal Behavior : 
Suicidal behavior was present during the assessment period?  Yes      No  
□   □  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  63 CONFIDENTIAL  Answer for Actual Attempts Only  Most Recent 
Attempt  
Date:  Most Lethal          
Attempt  
Date:  Initial/First 
Attempt 
Date:  
Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g., surface scratches). 
1.  Minor physical damage (e.g., lethargic speech; first -degree burns; mild bleeding; sprains).  
2.  Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat 
responsive; second -degree burns; bleeding of major vessel).  
3.  Moderately severe physical damage; medical  hospitalization and likely intensive care required 
(e.g., comatose with reflexes intact; third -degree burns less than 20% of body; extensive 
blood loss but can recover; major fractures).  
4.  Severe physical damage; medical  hospitalization with intensive care required (e.g., comatose 
without reflexes; third -degree burns over 20% of body; extensive b lood loss with unstable 
vital signs; major damage to a vital area).  
5.  Death   
Enter Code  
 
 
 
______  
 
 
  
Enter 
Code  
 
  
______  
 
 
  
Enter Code  
 
  
______  
 
 
 
Potential Lethality: Only Answer if Actual Lethality=0  
Likely lethality of actual attempt if no medical damage (the following examples, while having no 
actual medical damage, had potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with oncoming train but pulled away before run over).  
 
0 = Behavior not likely to result in injury  
1 = Behavior likely to result in injury but not likely to cause death  
2 = Behavior likely to result in death despite available medical care   
Enter Code  
 
 
 
______  
  
Enter 
Code  
 
  
______  
  
Enter Code  
   
______
 
  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  64 CONFIDENTIAL   
COLUMBIA- SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS)  
Since Last Visit Version  
Version 1/14/09 
 
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; 
Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J.   
 
 
Disclaimer:  
This scale is intended to be used by individuals who have received training in its administration. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suic idal ideation or behavior depends on the 
judgment of the individual administering the scale. 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia 
Suicide History Form , developed by John Mann, MD and Maria Oquendo, MD,  Conte Center 
for the Neuroscience of Mental Disorders (CCNMD), New York State Psychiatric Institute, 1051 
Riverside Drive, New York, NY, 10032. (Oquendo M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First [Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 
1051 Riverside Drive, New York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu  
© 2008 The Research Foundation for Mental Hygiene, Inc. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  65 CONFIDENTIAL   
SUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section. If the answer to 
question 2 is “yes”, ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete 
“Intensity of Ideation” section below.  Since 
Last 
Visit  
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
If yes, describe:   
Yes       No  
 □    □  
2.  Non -Specific Active Suicidal Thoughts  
General, non -specific thoughts of wanting to end one’s life/commit suicide (e.g., “I’ve thought about killing myself” ) without 
thoughts of ways to kill oneself/associated methods, intent, or plan during the assessment period.  
Have you actually had any thoughts of killing yourself?  
 
If yes, describe:  
 Yes      No  
  □    □  
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act  
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different t han 
a specific plan with time, place or method details worked out (e.g., thought of method to kill self but not a specific plan).  
Includes person who would say, “I thought about taking an overdose but I never made a specific plan as to when, where or 
how I would actually do it…and I would never go through with it.”  
Have you been thinking about how you might do this?  
 
If yes, describe:   
 Yes      No  
  □    □  
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan  
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts , as opposed to “I 
have the thoughts but I definitely will not do anything about them.”  
Have you had these thoughts and had some intention of acting on them ? 
 
If yes, describe:   
Yes       No  
  □    □  
5.  Active Suicidal Ideation with Specific Plan and Intent  
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out.  
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?  
 
If yes, describe:  
 Yes      No  
  □    □  
INTENSITY OF IDEATION  
The following features should be rated with respect to the most severe type of ideation (i.e., 1 -5 from above, with 
1 being the least severe and 5 being the most severe).  
 
Most Severe Ideation:             _____                      
_________________________________________________  
 
Type # (1 -5)                                         Description of  Ideation  Most 
Severe  
Frequency  
How many times have you had these thoughts?  
(1) Less than once a week    (2) Once a week   (3)  2 -5 times in week    (4) Daily or almost daily    (5) Many times each 
day  
____  
Duration  
When you have the thoughts, how long do they last?  
(1) Fleeting - few seconds or minutes                                                 (4) 4 -8 hours/most of day  
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or con tinuous  
(3) 1 -4 hours/a lot of time                                                                    ____  
Controllability  
Could/can you stop thinking about killing yourself or wanting to die if you want to?  
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of difficulty  
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts  
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts  ____  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  66 CONFIDENTIAL    Deterrents  
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from 
wanting to die or acting on thoughts of committing suicide?  
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterr ents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop  you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply  
 
 
 ____  
INTENSITY OF IDEATION  
Reasons for Ideation  
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to end 
the pain or stop the way you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?  
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you couldn’t go 
on 
(2) Mostly to get attention, revenge or a reaction from others                     living with the pain or how you were feeling)  
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you cou ldn’t 
go on  
       and to end/stop the pain                                                                         living with the pain or  how  you were feeling)  
                                                                                                                 (0)  Does not apply   
  
 
____  
Version 1/14/09 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  67 CONFIDENTIAL  SUICIDAL BEHAVIOR  
(Check all that apply, so long as these are separate events; must ask about all types)  Since 
Last 
Visit  
Actual Attempt:  
A potentially self -injurious act committed with at least some wish to die, as a result of act.  Behavior was in part thought of as 
method to kill oneself. Intent does not have to be 100%.  If there is any intent/desire to die associated with the act, then it can 
be considered an actual suicide attempt. There does not have to be any injury or harm , just the potential for injury or 
harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results, this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circums tances. 
For example, a highly lethal act that is clearly not an accident so no other  intent but suicide can be inferred (e.g., gunshot to 
head, jumping from window of a high floor/story). Also, if someone denies intent to die, but they thought that what they did 
could be lethal, intent may be inferred.  
Have you made a suicide attempt?  
Have you done anything to harm yourself?
  
Have you done anything dangerous where you could have died?  
What did you do?  
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you ___ __? 
Or did you think it was possible you could have died from_____?  
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, 
feel better, get sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)  
If yes, describe: 
  
Has subject engaged in Non -Suicidal Self -Injurious Behavior?   
Yes      No  
□   □  
 
 
 
  
 
 
Total # of  
Attempts  
 
______  
   
 
  
 
Yes     No  
□   □  
Interrupted Attempt:  
When the person is interrupted (by an outside circumstance) from starting the potentially self -injurious act(if not for that, actual 
attempt would have occurred).  
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather  
than an interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow 
prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, it is an attempt. Jumping: Person is 
poised to  jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck but has not yet started to hang - 
is stopped from doing so.  
Has there been a time when you started to do something to end your life but someone or something 
stopped you before you actually did anything?  
If yes, describe:  
Yes      No  
□   □  
 
 
Total # of 
interrupted  
 
______  
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in 
any self -destructive behavior. Examples are similar to interrupted attempts, except that the individual stops him/herself, instead 
of being stopped by something else.  
Has there been a time when you started to do something to try to end your life but you stopped 
yourself before you actually did anything? 
If yes, describe: 
  
Yes      No  
□   □  
 
Total # of  
aborted  
 
______  
Preparatory Acts  or Behavior:  
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought,  
such as assembling a specific method (e.g., buying pills, purchasing a gun) or preparing for one’s death by suicide (e.g., giving 
things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as 
collecting pills, getting a gun, giving valuables away or writing a suicide note )? 
If yes, describe: 
  
Yes      No 
□   □  
Suicidal Behavior : 
Suicidal behavior was present during the assessment period?  Yes      No  
□   □  
Suicide:  
   
    Yes    
No 
□   □  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  68 CONFIDENTIAL   
Answer for Actual Attempts Only  Most Lethal 
Attempt  
Date:  
Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g., surface scratches). 
1.  Minor physical damage (e.g., lethargic speech; first -degree burns; mild bleeding; sprains).  
2.  Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second -degree 
burns; bleeding of major vessel).  
3.  Moderately severe physical damage; medical  hospitalization and likely intensive care required (e.g., comatose with reflexes 
intact; third- degree burns less than 20% of body; extensive  blood loss but can recover; major fractures).  
4.  Severe physical damage; medical  hospitalization with intensive care required (e.g., comatose without reflexes; third -degree 
burns over 20% of body; extensive blood loss with unstable vital signs; major dam age to a vital area).  
5.  Death   
Enter 
Code  
 
  
______  
Potential Lethality: Only Answer if Actual Lethality=0  
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had 
potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on 
train tracks with oncoming train but pulled away before run over).  
 
0 = Behavior not likely to result in injury  
1 = Behavior likely to result i n injury but not likely to cause death  
2 = Behavior likely to result in death despite available medical care   
Enter 
Code  
 
  
______  
 
References  
 
K Posner; MA Oquendo; M Gould; B Stanley; M Davies. Columbia Classification Algorithm of 
Suicide Assessment (C -CASA): Classification of Suicidal Events in the FDA’s Pediatric Suicidal 
Risk Analysis of Antidepressants, Am J Psychiatry, 2007; 164:1035-1043.  
Center for Drug Evaluation and Research (CDER), Guidance for Industry Suicidality: Prospective 
Assessment of Occurrence in Clinical Trials. September 2010.  
K Posner; GK Brown; B Stanley; DA Brent; KV Yershova; MA Oquendo; GW Currier; GA Melvin; 
L Greenhill; S Shen; JJ Mann. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. Am J 
Psychiatry 2011;168:1266-1277. 
  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  69 CONFIDENTIAL   
COLUMBIA- SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS)  
Children’s Baseline/Screening  
Version 6/23/10 
 
 Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; 
Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J.   
 
 
Disclaimer:  
This scale is intended to be used by individuals who have received training in its administration. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale.  
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia 
Suicide History Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center 
for the Neuroscience of Mental Disorders (CCNMD), New York State Psychiatric Institute, 1051 
Riverside Drive, New York, NY, 10032. (Oquendo M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First [Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu 
© 2008 The Research Foundation for Mental Hygiene, Inc.  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  70 CONFIDENTIAL   
 
 
  
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  71 CONFIDENTIAL   
 
 
     

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  72 CONFIDENTIAL   
 
  

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  73 CONFIDENTIAL   
COLUMBIA- SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS)  
Children’s Since Last Visit Version  
Version 6/23/10 
 
 Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; 
Zelazny, J.; Burke, A.; Oquendo, M.; Mann, J.   
 
 
Disclaimer:  
This scale i s intended to be used by individuals who have received training in its administration. 
The questions contained in the Columbia-Suicide Severity Rating Scale are suggested probes. 
Ultimately, the determination of the presence of suicidal ideation or behavior depends on the 
judgment of the individual administering the scale. 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia 
Suicide History Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center 
for the Neuroscience of Mental Disorders (CCNMD), New York State Psychiatric Institute, 1051 
Riverside Drive, New York, NY, 10032. (Oquendo M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First [Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu 
© 2008 The Research Foundation for Mental Hygiene, Inc. 
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  74 CONFIDENTIAL   
  
  

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  75 CONFIDENTIAL   
 
     

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  76 CONFIDENTIAL   
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  77 CONFIDENTIAL  APPENDIX C: NIH TOOLBOX ODOR 
IDENTIFICATION TEST  
 
This test assesses a person’s ability to identify various odors.  Participants use scratch ’n’ sniff 
cards and after scratching them one at a time, are asked to identify which of four pictures on the computer screen matches the odor th ey have just smelled.  
Participants ages 10 -85 are administered nine odor cards, while those ages 3- 9 are administered 
five odor cards. Child participants (ages 3 -9 years) are first asked to identify the eight pictures that are used as answer choices, to ensure they can complete the task.   Having identified the 
pictures, they are asked if they have tasted or smelled the objects or foods depicted.  
This test takes approximately 4 to 5 minutes to administer and is recommended for ages 3-85.    http://www.nihtoolbox.org/WhatAndWhy/Sensation/Olfaction/Pages/NIH-Toolbox-Odor-
Identification -Test.aspx  
  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  78 CONFIDENTIAL  APPENDIX D: QUALITY OF LIFE IN EPILEPSY 
(QOLIE)  
Quality of Life in Epilepsy will be administered to assess the quality of life while on NRL -1 
compared to baseline therapy at time of enrollment.  QOLIE -AD-48 will be used for subjects age 
11-18 years with epilepsy.  S ubjects age 18 years or older should complete the QOLIE-31-P. If 
under the age of 11, no Quality of Life questionnaire will be administered. 
 
  
Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  79 CONFIDENTIAL   

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  80 CONFIDENTIAL   

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  81 CONFIDENTIAL   

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  82 CONFIDENTIAL   
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  83 CONFIDENTIAL   
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  84 CONFIDENTIAL   
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  85 CONFIDENTIAL   
 
  

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  86 CONFIDENTIAL   
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  87 CONFIDENTIAL   
 
    

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  88 CONFIDENTIAL   
 
 
    

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  89 CONFIDENTIAL   
 
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  90 CONFIDENTIAL   
 
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  91 CONFIDENTIAL   
 
      

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  92 CONFIDENTIAL   
 
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  93 CONFIDENTIAL   
 
 

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  94 CONFIDENTIAL   
 
     

Neurelis, Inc.  Protocol DIAZ.001.05  
NRL -1 (Diazepam Intranasal)  Version:  4 
 
28 September  2017  95 CONFIDENTIAL   
 
 
    

Neurelis, Inc. Protocol DIAZ.001.05 
NRL-1 (Diazepam Intranasal) Version:  4  
 
28 September 2017 96 CONFIDENTIAL  APPENDIX E: DIRECTIONS FOR USE 
NRL-1 INSTRUCTION GUIDE 
FOR INVESTIGATIONAL USE ONLY.  KEEP OUT OF REACH OF CHILDREN.  
IMPORTANT: FOR USE IN THE NOSE ONLY.  
DO NOT REMOVE OR TEST THE NRL-1 NASAL SPRAY ER UNTIL READY TO USE.  
 
Neurelis, Inc.  
Version Date: 07 JUNE  2016  
Identify 
Seizure 
Occurrence  
 
 Safely Secure the Person 
During a Seizure:  
• Stay Calm  
• If the person appears 
to be having a seizure and is standing , 
prevent them from falling by holding in a 
hug, or try to help them gently to the floor and 
lay the person on their side 
• If the person having a seizure is on the ground when you arrive, try to position them on their side  so 
that any saliva or vomit may leak out of their mouth 
• Move furniture or other objects  away to 
prevent injury to the 
person during the seizure
  
Give 
NRL-1 
Nasal Spray  HOLD
• The person can be in 
any position to receive a 
dose of NRL-1 nasal 
spray   the NRL-1 nasal 
spray with your thumb on the bottom of the nasal 
spray  and your first and 
middle fingers on either side of the nozzle.  
 
• Insert the tip of the 
nozzle  into one nostril , 
until your fingers  on 
either  side of the nozzle  
are against the bottom  
of the patient’s  nose  Gently insert the tip of 
the nozzle into either 
nostril.  
Press the bottom of the 
nasal spray firmly
• Remove the NRL -1 
nasal spray  from the 
nose  to give 
the dose of NRL-1 nasal 
spray.   
For 15mg or 20mg dose, 
repeat with second 
sprayer in other nostril  After the 
Seizure : 
Evaluate and Support  Check the person for 
injuries.   
Move the person on their 
side (recovery position)  
if you could not turn the person onto their side during the seizure
. 
Loosen tight clothing and 
provide a safe area where the person can rest  
Keep the person on their 
side
Your doctor may prescribe an  
and note the time 
NRL-1 was given and 
observe  
additional 
dose  of NRL -1 spray 
which  may be given 
4 hours after the first 
dose.   Repeat  Step 2
  to 
give another dose of NRL- 1 
nasal spray.  3 2 1 
Not more than 2 doses per seizure episode.  Call 911 if seizure does not subside after second dose of NRL -1.  Allow 5 days before repeating dose.  
 